<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41679247</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9452</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><PubDate><Year>2026</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>Molecular aspects of medicine</Title><ISOAbbreviation>Mol Aspects Med</ISOAbbreviation></Journal><ArticleTitle>Impact of type 2 diabetes on malignancies of the female reproductive system.</ArticleTitle><Pagination><StartPage>101459</StartPage><MedlinePgn>101459</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mam.2026.101459</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0098-2997(26)00015-4</ELocationID><Abstract><AbstractText>Type 2 diabetes mellitus (T2DM) contributes significantly to the development and progression of cancers of the female reproductive tissues, particularly endometrial, ovarian, and breast. Hallmarks of T2DM, such as hyperinsulinemia, insulin resistance, and chronic low-grade inflammation, disrupt endocrine and metabolic homeostasis, promoting carcinogenesis through enhanced mitogenic signaling, hormonal dysregulation, and immune activation. T2DM can alter ovarian, endometrial, and mammary physiology by affecting estrogen/progesterone receptor activity, stromal remodeling, and specialized cell function. Furthermore, give the fluctuations in a woman's hormonal levels and reproductive status, the presence of excess weight and T2DM may have altering risks depending on the lifecycle. These effects are exacerbated by adipose-derived cytokines and leptin resistance, further amplifying estrogens' bioavailability and pro-inflammatory signaling. Endometrial cancer risk is nearly doubled in diabetic women, independent of body mass index, with hyperglycemia inducing PI3K/AKT/mTOR and NF-&#x3ba;B pathway activation, reduced sex hormone-binding globulin (SHBG) levels, and upregulation of estrogen receptor signaling. Ovarian cancer in diabetic patients is associated with more aggressive histological subtypes, advanced-stage presentation, and poorer survival, likely driven by Insulin-like growth factor 1 (IGF-1) signaling, oxidative stress, and impaired treatment response. Similarly, T2DM increases the risk and worsens outcomes in breast cancer via enhanced expression, AGE-RAGE interactions, and estrogen-independent ER&#x3b1; activation. Herein, we synthesize current epidemiological evidence and mechanistic insights to delineate the multifaceted relationship between T2DM and these cancers. Despite increased risk, diabetic women often face underdiagnosis due to suboptimal screening practices. As T2DM prevalence rises globally, tailored cancer prevention and treatment strategies for diabetic populations are urgently needed. Metformin has shown robust benefits in reducing T2DM-related complications and potential in the antineoplastic setting. This review underscores the endocrine and inflammatory mechanisms linking T2DM to cancers of the female reproductive system and advocates for integrated clinical protocols that include early screening and individualized management in diabetic women.</AbstractText><CopyrightInformation>Copyright &#xa9; 2026 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Espinoza</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Biological Sciences, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, Chile; Center for Cancer prevention and Control (FONDAP-CECAN), Pontificia Universidad Cat&#xf3;lica de Chile), Santiago, Chile; Millennium Institute on Immunology and Immunotherapy, Santiago, 8331150, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veas-Torres</LastName><ForeName>Javiera</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Biological Sciences, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, Chile; Center for Cancer prevention and Control (FONDAP-CECAN), Pontificia Universidad Cat&#xf3;lica de Chile), Santiago, Chile; Millennium Institute on Immunology and Immunotherapy, Santiago, 8331150, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Daniela I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Biological Sciences, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, Chile; Center for Cancer prevention and Control (FONDAP-CECAN), Pontificia Universidad Cat&#xf3;lica de Chile), Santiago, Chile; Millennium Institute on Immunology and Immunotherapy, Santiago, 8331150, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Gareth I</ForeName><Initials>GI</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Biological Sciences, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, Chile; Department of Hematology and Oncology, Faculty of Medicine, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, Chile; Center for Cancer prevention and Control (FONDAP-CECAN), Pontificia Universidad Cat&#xf3;lica de Chile), Santiago, Chile; Millennium Institute on Immunology and Immunotherapy, Santiago, 8331150, Chile. Electronic address: gowen@uc.cl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Aspects Med</MedlineTA><NlmUniqueID>7603128</NlmUniqueID><ISSNLinking>0098-2997</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">Endometrial cancer</Keyword><Keyword MajorTopicYN="N">Estrogen</Keyword><Keyword MajorTopicYN="N">Gynecological cancer</Keyword><Keyword MajorTopicYN="N">Hormonal dysregulation</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Insulin resistance</Keyword><Keyword MajorTopicYN="N">Metabolic reprogramming</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">Ovarian cancer</Keyword><Keyword MajorTopicYN="N">PI3K/AKT pathway</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2026</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>13</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>13</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>12</Day><Hour>18</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41679247</ArticleId><ArticleId IdType="doi">10.1016/j.mam.2026.101459</ArticleId><ArticleId IdType="pii">S0098-2997(26)00015-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41670332</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Maternal-to-Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A&#xa0;Systematic Review of Available Evidence and&#xa0;Clinical Guidelines.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.70211</ELocationID><Abstract><AbstractText>This review evaluates the available pharmacokinetic data on the plasma-to-breastmilk transfer of first- and second-line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines. A systematic search of research articles reporting human plasma and breastmilk drug concentrations was conducted in Scopus, PubMed, Google Scholar, and LactMed&#xae; in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies evaluating breastmilk drug transfer in T2DM, with fully accessible abstract and main text reported in English, were included. Study quality was evaluated using the ClinPK checklist. Authors evaluated clinical guideline recommendations on the use of T2DM drugs in lactation and the basis upon which such recommendations were made. Only 5 out of 20 drugs (metformin, glyburide, glipizide, tolbutamide, and semaglutide) have clinical data on plasma-to-breastmilk transfer. Metformin and tolbutamide were detectable in maternal plasma and breastmilk. Half (51.7%) of guideline recommendations provide explicit guidance. Only 4.4% of recommendations were based on clinical evidence. Over half (57.8%) of recommendations were accessible online, and most guideline recommendations (78%) were against the use of antiglycemic agents while breastfeeding. The scarce clinical evidence to guide T2DM drug therapy during breastfeeding available has several design and methodological limitations. Published recommendations remain largely inconsistent, thus perpetuating uncertainty in the use of T2DM drug therapies in lactation. Addressing knowledge gaps is critical in developing clinical consensus to optimize T2DM drug therapy among breastfeeding mothers.</AbstractText><CopyrightInformation>&#xa9; 2026 The Author(s). Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0007-3491-1514</Identifier><AffiliationInfo><Affiliation>School of Medicine, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiptoo</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8077-6666</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Institute, Makerere University, Kampala, Uganda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Faculty of Medicine, Mbarara University of Science &amp; Technology, Mbarara, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mpora Odongkara</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6283-9114</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics &amp; Child Health, Faculty of Medicine, Gulu University, Gulu, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ojara</LastName><ForeName>Francis Williams</ForeName><Initials>FW</Initials><Identifier Source="ORCID">0000-0002-6425-6828</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Institute, Makerere University, Kampala, Uganda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, Faculty of Medicine, Gulu University, Gulu, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waitt</LastName><ForeName>Catriona</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0134-5855</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Institute, Makerere University, Kampala, Uganda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Women's and Children's Health, School of Medicine, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>INV052005</GrantID><Acronym>GATES</Acronym><Agency>Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>222075/Z/20/Z</GrantID><Agency>Wellcome Clinical Research Career Development Fellowship</Agency><Country/></Grant><Grant><GrantID>NIHR304266</GrantID><Agency>NIHR Global Health Research Professorship</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>11</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>11</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>11</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41670332</ArticleId><ArticleId IdType="doi">10.1002/cpt.70211</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ong, K.L. et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet 402, 203&#x2013;234 (2023).</Citation></Reference><Reference><Citation>Wright, A.K. et al. Life expectancy and cause&#x2010;specific mortality in type 2 diabetes: a population&#x2010;based cohort study quantifying relationships in ethnic subgroups. Diabetes Care 40, 338&#x2013;345 (2017).</Citation></Reference><Reference><Citation>Usman, M.S., Khan, M.S. &amp; Butler, J. The interplay between diabetes, cardiovascular disease, and kidney disease. In Chronic Kidney Disease and Type 2 Diabetes (American Diabetes Association, 2021) &lt;http://www.ncbi.nlm.nih.gov/books/NBK571718/&gt;. Accessed May 22, 2025.</Citation></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes&#x2014;2025. Diabetes Care 48(Suppl 1), S181&#x2013;S206 (2024).</Citation></Reference><Reference><Citation>Mazer&#x2010;Amirshahi, M., Samiee&#x2010;Zafarghandy, S., Gray, G. &amp; van den Anker, J.N. Trends in pregnancy labeling and data quality for US&#x2010;approved pharmaceuticals. Am. J. Obstet. Gynecol. 211, 690.e1&#x2013;690.e11 (2014).</Citation></Reference><Reference><Citation>Victora, C.G. et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet 387, 475&#x2013;490 (2016).</Citation></Reference><Reference><Citation>World Health Organization. Breastfeeding &lt;https://www.who.int/data/nutrition/tracking&#x2010;tool/breastfeeding&gt; (2020). Accessed April 15, 2025.</Citation></Reference><Reference><Citation>World Health Organization. Global breastfeeding scorecard 2022: protecting breastfeeding through further investments and policy actions &lt;https://iris.who.int/bitstream/handle/10665/365140/WHO&#x2010;HEP&#x2010;NFS&#x2010;22.6&#x2010;eng.pdf?sequence=1&gt; (2022). Accessed May 22, 2025.</Citation></Reference><Reference><Citation>Odom, E.C., Li, R., Scanlon, K.S., Perrine, C.G. &amp; Grummer&#x2010;Strawn, L. Reasons for earlier than desired cessation of breastfeeding. Pediatrics 131, e726&#x2013;e732 (2013).</Citation></Reference><Reference><Citation>Gunderson, E.P. et al. Childbearing may increase visceral adipose tissue independent of overall increase in body fat. Obesity (Silver Spring) 16, 1078&#x2013;1084 (2008).</Citation></Reference><Reference><Citation>Chen, J., Fu, D., Ma, T., Chen, M., Wang, X. &amp; Yi, J. Global burden of metabolic disorders among women of child&#x2010;bearing age, 1990&#x2013;2021: a population&#x2010;based study. BMC Womens Health 25, 207 (2025).</Citation></Reference><Reference><Citation>Horta, B.L., Loret de Mola, C. &amp; Victora, C.G. Long&#x2010;term consequences of breastfeeding on cholesterol, obesity, systolic blood pressure and type 2 diabetes: a systematic review and meta&#x2010;analysis. Acta Paediatr. 104, 30&#x2013;37 (2015).</Citation></Reference><Reference><Citation>Bobrow, K.L., Quigley, M.A., Green, J., Reeves, G.K. &amp; Million Women Study Collaborators. Persistent effects of women&#x2019;s parity and breastfeeding patterns on their body mass index: results from the million women study. Int. J. Obes. (Lond) 37, 712&#x2013;717 (2013).</Citation></Reference><Reference><Citation>Belete, T.M. A recent achievement in the discovery and development of novel targets for the treatment of type&#x2010;2 diabetes mellitus. J. Exp. Pharmacol. 12, 1&#x2013;15 (2020).</Citation></Reference><Reference><Citation>Royal Australian College of General Practitioners. Management of Type 2 Diabetes: A Handbook for General Practice &lt;https://www.racgp.org.au/getattachment/00186565&#x2010;b7b3&#x2010;4eb8&#x2010;aefb&#x2010;e7f8ff3973d5/Management&#x2010;of&#x2010;type&#x2010;2&#x2010;diabetes&#x2010;A&#x2010;handbook&#x2010;for&#x2010;general&#x2010;practice.aspx&gt; (2024). Accessed February 27, 2025.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Type 2 Diabetes in Adults. Quality Standard QS209 &lt;https://www.nice.org.uk/guidance/qs209&gt; (2023). Accessed February 26, 2025.</Citation></Reference><Reference><Citation>Uganda Ministry of Health. Uganda Clinical Guidelines, 2023 &lt;https://library.health.go.ug/uganda&#x2010;clinical&#x2010;guidelines&#x2010;2023&gt; (2023) Accessed April 10, 2025.</Citation></Reference><Reference><Citation>Blundell, J. et al. Effects of once&#x2010;weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes. Metab. 19, 1242&#x2013;1251 (2017).</Citation></Reference><Reference><Citation>Verdich, C., Toubro, S., Buemann, B., Lysg&#xe5;rd Madsen, J., Juul Holst, J. &amp; Astrup, A. The role of postprandial releases of insulin and incretin hormones in meal&#x2010;induced satiety&#x2013;effect of obesity and weight reduction. Int. J. Obes. Relat. Metab. Disord. 25, 1206&#x2013;1214 (2001).</Citation></Reference><Reference><Citation>US Food and Drug Administration. Clinical lactation studies: considerations for study design guidance for industry (2019).</Citation></Reference><Reference><Citation>Chivese, T. et al. IDF diabetes atlas: the prevalence of pre&#x2010;existing diabetes in pregnancy &#x2013; a systematic review and meta&#x2010;analysis of studies published during 2010&#x2013;2020. Diabetes Res. Clin. Pract. 183, 109049 (2022).</Citation></Reference><Reference><Citation>Rowland Yeo, K., Gerhart, J., Sawant&#x2010;Basak, A., Ojara, F.W., Kawuma, A.N. &amp; Waitt, C. Clinical lactation studies. Acting on key recommendations over the last decade. NPJ Womens Health 3, 19 (2025).</Citation></Reference><Reference><Citation>Briggs, G.G., Ambrose, P.J., Nageotte, M.P., Padilla, G. &amp; Wan, S. Excretion of metformin into breast milk and the effect on nursing infants. Obstet. Gynecol. 105, 1437&#x2013;1441 (2005).</Citation></Reference><Reference><Citation>Eyal, S. et al. Pharmacokinetics of metformin during pregnancy. Drug Metab. Dispos. 38, 833&#x2013;840 (2010).</Citation></Reference><Reference><Citation>Gardiner, S.J., Kirkpatrick, C.M.J., Begg, E.J., Zhang, M., Moore, M.P. &amp; Saville, D.J. Transfer of metformin into human milk. Clin. Pharmacol. Ther. 73, 71&#x2013;77 (2003).</Citation></Reference><Reference><Citation>Hale, T., Kristensen, J., Hackett, L., Kohan, R. &amp; Ilett, K. Transfer of metformin into human milk. Diabetologia 45, 1509&#x2013;1514 (2002).</Citation></Reference><Reference><Citation>Gardiner, S.J., Kirkpatrick, C.M.J., Zhang, M. &amp; Begg, E.J. Cimetidine does not appear to influence the distribution of metformin into human milk. Br. J. Clin. Pharmacol. 66, 564&#x2013;565 (2008).</Citation></Reference><Reference><Citation>Moiel, R.H. &amp; Ryan, J.R. Tolbutamide orinase in human breast milk. Clin. Pediatr. (Phila) 6, 480 (1967).</Citation></Reference><Reference><Citation>Feig, D.S. et al. Transfer of glyburide and glipizide into breast milk. Diabetes Care 28, 1851&#x2013;1855 (2005).</Citation></Reference><Reference><Citation>Diab, H., Fuquay, T., Datta, P., Bickel, U., Thompson, J. &amp; Krutsch, K. Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk. Nutrients 16, 2886 (2024).</Citation></Reference><Reference><Citation>Kanji, S. et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin. Pharmacokinet. 54, 783&#x2013;795 (2015).</Citation></Reference><Reference><Citation>US Food and Drug Administration. Bioanalytical method validation guidance for industry (2018).</Citation></Reference><Reference><Citation>Begg, E.J., Duffull, S.B., Hackett, L.P. &amp; Ilett, K.F. Studying drugs in human milk: time to unify the approach. J. Hum. Lact. 18, 323&#x2013;332 (2002).</Citation></Reference><Reference><Citation>Anderson, P.O. &amp; Sauberan, J.B. Modeling drug passage into human milk. Clin. Pharmacol. Ther. 100, 42&#x2013;52 (2016).</Citation></Reference><Reference><Citation>Rane, A. Determinants of drug disposition in infants. In Drugs and Human Lactation 2nd edn. (ed. Bennett, P.N.) 59&#x2013;66 (Elsevier Science B.V, Amsterdam, Netherlands, 1996).</Citation></Reference><Reference><Citation>Derbyshire Joint Prescribing Committee. JPAC Report &lt;https://www.derbyshiremedicinesmanagement.nhs.uk/assets/Clinical_Guidelines/Formulary_by_BNF_chapter_prescribing_guidelines/BNF_chapter_6/Glucose_control_in_Type_2_Diabetes.pdf&gt; (2022). Accessed February 27, 2025.</Citation></Reference><Reference><Citation>North East London Integrated Medicines Optimization and Prescribing Group. Type 2 diabetes management guideline (NHS) &lt;https://primarycare.northeastlondon.icb.nhs.uk/wp&#x2010;content/uploads/2024/01/Type&#x2010;2&#x2010;diabetes&#x2010;management&#x2010;guideline&#x2010;NEL&#x2010;V2_12.2023.pdf&gt; (2023). Accessed February 27, 2025.</Citation></Reference><Reference><Citation>National Center for Biotechnology Information. LactMed &lt;https://www.ncbi.nlm.nih.gov/books/NBK501922/&gt; (2025). Accessed March 20, 2025.</Citation></Reference><Reference><Citation>World Health Organization. Management of Diabetes Mellitus: Standards of Care and Clinical Practice Guidelines &lt;https://applications.emro.who.int/dsaf/dsa509.pdf&gt; (1994).</Citation></Reference><Reference><Citation>Organization of Teratology Information Specialists. MotherToBaby &lt;https://mothertobaby.org/fact&#x2010;sheets/&gt; (2024). Accessed March 20, 2025.</Citation></Reference><Reference><Citation>Electronic Medicines Compendium. Home &#x2010; electronic medicines compendium (emc) [Internet]. &lt;https://www.medicines.org.uk/.&gt; (2025).</Citation></Reference><Reference><Citation>Fortinguerra, F., Clavenna, A. &amp; Bonati, M. Psychotropic drug use during breastfeeding: a review of the evidence. Pediatrics 124, e547&#x2013;e556 (2009).</Citation></Reference><Reference><Citation>Berle, J.&#xd8;., Steen, V.M., Aamo, T.O., Breilid, H., Zahlsen, K. &amp; Spigset, O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J. Clin. Psychiatry 65, 1228&#x2013;1234 (2004).</Citation></Reference><Reference><Citation>Nordeng, H., Havnen, G.C. &amp; Spigset, O. Drug use and breastfeeding. Tidsskr. Nor. Laegeforen. 132, 1089&#x2013;1092 (2012).</Citation></Reference><Reference><Citation>van Wattum, J.J., Leferink, T.M., Wilffert, B. &amp; ter Horst, P.G.J. Antibiotics and lactation: an overview of relative infant doses and a systematic assessment of clinical studies. Basic Clin. Pharmacol. Toxicol. 124, 5&#x2013;17 (2019).</Citation></Reference><Reference><Citation>Rentsch, K.M. Drug exposure in newborns: effect of selected drugs prescribed to mothers during pregnancy and lactation. Ther. Drug Monit. 42, 255&#x2013;267 (2020).</Citation></Reference><Reference><Citation>Qasqas, S.A., McPherson, C., Frishman, W.H. &amp; Elkayam, U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol. Rev. 12, 201&#x2013;221 (2004).</Citation></Reference><Reference><Citation>Byrne, J.J., Saucedo, A.M. &amp; Spong, C.Y. Evaluation of drug labels following the 2015 pregnancy and lactation labeling rule. JAMA Netw. Open 3, e2015094 (2020).</Citation></Reference><Reference><Citation>Bennett, P.N. &amp; Jensen, A.A. Drugs and Human Lactation: A Comprehensive Guide to the Content and Consequences of Drugs, Micronutrients, Radiopharmaceuticals, and Environmental and Occupational Chemicals in Human Milk 2nd edn. (Elsevier, Amsterdam, Netherlands, 1996).</Citation></Reference><Reference><Citation>T&#xfc;rk, D. et al. Significant impact of time&#x2010;of&#x2010;day variation on metformin pharmacokinetics. Diabetologia 66, 1024&#x2013;1034 (2023).</Citation></Reference><Reference><Citation>Wang, J. et al. Evaluation of the safety of drugs and biological products used during lactation: workshop summary. Clin. Pharmacol. Ther. 101, 736&#x2013;744 (2017).</Citation></Reference><Reference><Citation>Ballard, O. &amp; Morrow, A.L. Human milk composition: nutrients and bioactive factors. Pediatr. Clin. North Am. 60, 49&#x2013;74 (2013).</Citation></Reference><Reference><Citation>Saarela, T., Kokkonen, J. &amp; Koivisto, M. Macronutrient and energy contents of human milk fractions during the first six months of lactation. Acta Paediatr. 94, 1176&#x2013;1181 (2005).</Citation></Reference><Reference><Citation>Kent, J.C., Mitoulas, L.R., Cregan, M.D., Ramsay, D.T., Doherty, D.A. &amp; Hartmann, P.E. Volume and frequency of breastfeedings and fat content of breast milk throughout the day. Pediatrics 117, e387&#x2013;e395 (2006).</Citation></Reference><Reference><Citation>Lawrence, R.A. Physiology of lactation. In Breastfeeding 9th edn. (eds. Lawrence, R.A. &amp; Lawrence, R.M.) 65&#x2013;95 (Elsevier, Philadelphia, 2022).</Citation></Reference><Reference><Citation>Gabery, S. et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 5, e133429 (2020).</Citation></Reference><Reference><Citation>Chinese Geriatric Type 2 Diabetes Prevention and Treatment Clinical Guidelines Writing Group, Chinese Geriatric Medicine Society Geriatric Endocrinology and Metabolism Branch, Chinese Geriatric Health Care Medicine Research Association Geriatric Endocrinology and Metabolism Branch, Beijing Medical Award Foundation Geriatric Medicine Professional Committee, National Clinical Medical Research Center for Geriatric Diseases (PLA General Hospital). Chinese geriatric type 2 diabetes prevention and treatment clinical guidelines (2022 edition). Chin. J. Intern. Med. 61, 12&#x2013;50 (2022).</Citation></Reference><Reference><Citation>Atkinson, H. &amp; Begg, E. Prediction of drug concentrations in human skim milk from plasma protein binding and acid&#x2010;base characteristics. Br. J. Clin. Pharmacol. 25, 495&#x2013;503 (1988).</Citation></Reference><Reference><Citation>Knox, C. et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 52(D1), D1265&#x2013;D1275 (2024).</Citation></Reference><Reference><Citation>Abduljalil, K., Pansari, A., Ning, J. &amp; Jamei, M. Prediction of drug&#xa0;concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically&#x2010;based pharmacokinetic model. CPT Pharmacometrics Syst. Pharmacol. 10, 878&#x2013;889 (2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41668763</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Mechanistic and therapeutic dimensions of DcR3-mediated immunomodulation in sepsis.</ArticleTitle><Pagination><StartPage>1750066</StartPage><MedlinePgn>1750066</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1750066</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2025.1750066</ELocationID><Abstract><AbstractText>Sepsis is a life-threatening syndrome characterized by dysregulated host-immune responses, progressing through hyperinflammatory and immunosuppressive stages. Decoy receptor 3 (DcR3), a soluble member of the TNF receptor superfamily, serves as an immunomodulator in sepsis. Beyond neutralizing FasL, LIGHT, and TL1A to block apoptosis and inflammatory signaling, DcR3 regulates macrophage polarization, dendritic cell maturation, and immune cell survival through its heparan sulfate proteoglycan-binding domain. Evidence from cellular, molecular, and animal studies highlights its dual role in restoring immune balance by modulating both hyperinflammatory and immunosuppressive phases of sepsis. In this review, we summarize current evidence on DcR3 in sepsis and discuss translational challenges and future directions. Current rodent models lacking the TNFRSF6B gene are limited; however, transgenic mice expressing human DcR3 exhibit both protective and detrimental context-dependent effects. Translational challenges include the pharmacokinetics and immunogenicity of recombinant DcR3, although strategies such as PEGylation, nanoparticle encapsulation, and hydrogel delivery may improve its efficacy. Combining DcR3 with PD-1/PD-L1 inhibitors or immunometabolic agents like metformin and dimethyl itaconate presents promising therapeutic potential. Future research will focus on CRISPR/Cas9 knock-in mouse models, multi-omics mapping of DcR3 signaling, and biomarker-guided dosing. Although no DcR3-targeted clinical trials in sepsis have been conducted, DcR3 remains a precision-targeted immunotherapy with mechanistic and translational pathways; this review delineates key knowledge gaps that must be addressed to enable future clinical application.</AbstractText><CopyrightInformation>Copyright &#xa9; 2026 Abbas, Lin, Xu, Chen and Su.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Abbas</LastName><ForeName>Bilal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, Fujian,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lin</LastName><ForeName>Xinrui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, Fujian,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, Fujian,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, Fujian,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Jingqian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, Fujian,&#xa0;China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053323">Receptors, Tumor Necrosis Factor, Member 6b</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C505911">TNFRSF6B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053323" MajorTopicYN="Y">Receptors, Tumor Necrosis Factor, Member 6b</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="Y">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DcR3</Keyword><Keyword MajorTopicYN="N">FasL</Keyword><Keyword MajorTopicYN="N">TL1A</Keyword><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">immunomodulation</Keyword><Keyword MajorTopicYN="N">light</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword></KeywordList><CoiStatement>The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>11</Day><Hour>4</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>1</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41668763</ArticleId><ArticleId IdType="pmc">PMC12884390</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2025.1750066</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arwyn-Jones J, Brent AJ. Sepsis. Surg Oxford. (2025) 43:430&#x2013;7. doi:&#xa0; 10.1016/j.mpsur.2025.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mpsur.2025.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>La Via L, Sangiorgio G, Stefani S, Marino A, Nunnari G, Cocuzza S, et al. The global burden of sepsis and septic shock. Epidemiologia. (2024) 5:456&#x2013;78. doi:&#xa0; 10.3390/epidemiologia5030032, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/epidemiologia5030032</ArticleId><ArticleId IdType="pmc">PMC11348270</ArticleId><ArticleId IdType="pubmed">39189251</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Liu C-F. Sepsis heterogeneity. World J Pediatr. (2023) 19:919&#x2013;27. doi:&#xa0; 10.1007/s12519-023-00689-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-023-00689-8</ArticleId><ArticleId IdType="pubmed">36735197</ArticleId></ArticleIdList></Reference><Reference><Citation>Naghavi M, Mestrovic T, Gray A, Hayoon AG, Swetschinski LR, Aguilar GR, et al. Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Infect Dis. (2024) 24:868&#x2013;95. doi:&#xa0; 10.1016/S1473-3099(24)00158-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00158-0</ArticleId><ArticleId IdType="pmc">PMC11269650</ArticleId><ArticleId IdType="pubmed">38640940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjit S, Kissoon N. Challenges and solutions in translating sepsis guidelines into practice in resource-limited settings. Trans Pediatr. (2021) 10:2646. doi:&#xa0; 10.21037/tp-20-310, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tp-20-310</ArticleId><ArticleId IdType="pmc">PMC8578780</ArticleId><ArticleId IdType="pubmed">34765491</ArticleId></ArticleIdList></Reference><Reference><Citation>Joosten SC, Wiersinga WJ, van der Poll T. eds. Dysregulation of host&#x2013;Pathogen interactions in sepsis: host-Related factors. In: Seminars in Respiratory and Critical Care Medicine. Thieme Medical Publishers, Inc. doi:&#xa0; 10.1055/s-0044-1787554, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0044-1787554</ArticleId><ArticleId IdType="pmc">PMC11663080</ArticleId><ArticleId IdType="pubmed">38950605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, van der Poll T. Immunopathophysiology of human sepsis. EBioMedicine. (2022) 86:104363. doi:&#xa0; 10.1016/j.ebiom.2022.104363, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104363</ArticleId><ArticleId IdType="pmc">PMC9783164</ArticleId><ArticleId IdType="pubmed">36470832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wu X, Zhang W, Pu Y, Xu X, Sun Y, et al. Predictive value of risk factors for prognosis of patients with sepsis in intensive care unit. Medicine. (2023) 102:e33881. doi:&#xa0; 10.1097/MD.0000000000033881, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000033881</ArticleId><ArticleId IdType="pmc">PMC10256413</ArticleId><ArticleId IdType="pubmed">37335653</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacroce E, D&#x2019;Angerio M, Ciobanu AL, Masini L, Lo Tartaro D, Coloretti I, et al. Advances and challenges in sepsis management: modern tools and future directions. Cells. (2024) 13:439. doi:&#xa0; 10.3390/cells13050439, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells13050439</ArticleId><ArticleId IdType="pmc">PMC10931424</ArticleId><ArticleId IdType="pubmed">38474403</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques A, Torre C, Pinto R, Sepodes B, Rocha J. Treatment advances in sepsis and septic shock: modulating pro-and anti-inflammatory mechanisms. J Clin Med. (2023) 12:2892. doi:&#xa0; 10.3390/jcm12082892, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12082892</ArticleId><ArticleId IdType="pmc">PMC10142733</ArticleId><ArticleId IdType="pubmed">37109229</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Tong Z, Wu S, Zhou F, Chen Q. Research progress of Dcr3 in the diagnosis and treatment of sepsis. Int J Mol Sci. (2023) 24:12916. doi:&#xa0; 10.3390/ijms241612916, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241612916</ArticleId><ArticleId IdType="pmc">PMC10454171</ArticleId><ArticleId IdType="pubmed">37629097</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagou S, Grapsa D, Syrigos N, Bamias G. The role of decoy receptor DcR3 in gastrointestinal Malignancy. Cancer Diagn Progn. (2022) 2:411. doi:&#xa0; 10.21873/cdp.10124, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/cdp.10124</ArticleId><ArticleId IdType="pmc">PMC9254098</ArticleId><ArticleId IdType="pubmed">35813013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kural A. DcR3 in all its aspects. Bagc&#x131;lar Med Bull. (2022) 7:90&#x2013;101. doi:&#xa0; 10.4274/galenos.2022.2022-04-032</Citation><ArticleIdList><ArticleId IdType="doi">10.4274/galenos.2022.2022-04-032</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Chen W, Zhou F, Li R, Tong Z, Wu S, et al. Inhibitory mechanisms of decoy receptor 3 in cecal ligation and puncture-induced sepsis. Mbio. (2024) 15:e00521&#x2013;24. doi:&#xa0; 10.1128/mbio.00521-24, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00521-24</ArticleId><ArticleId IdType="pmc">PMC11237498</ArticleId><ArticleId IdType="pubmed">38700314</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Tong Z, Feng Z, Wu S, Zhou F, Li R, et al. Protective effects of DcR3-SUMO on lipopolysaccharide-induced inflammatory cells and septic mice. Int J Biol Macromol. (2024) 275:133703. doi:&#xa0; 10.1016/j.ijbiomac.2024.133703, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2024.133703</ArticleId><ArticleId IdType="pubmed">38986982</ArticleId></ArticleIdList></Reference><Reference><Citation>Min D, Wu B, Chen L, Chen R, Wang J, Zhang H, et al. Level of decoy receptor 3 for monitoring clinical progression of severe burn patients. J Burn Care Res. (2021) 42:925&#x2013;33. doi:&#xa0; 10.1093/jbcr/irz170, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jbcr/irz170</ArticleId><ArticleId IdType="pubmed">34213565</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli G, Vacher P, Ryffel B, Blanco P, Legembre P. Fas/CD95 signaling pathway in damage-associated molecular pattern (DAMP)-sensing receptors. Cells. (2022) 11:1438. doi:&#xa0; 10.3390/cells11091438, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11091438</ArticleId><ArticleId IdType="pmc">PMC9105874</ArticleId><ArticleId IdType="pubmed">35563744</ArticleId></ArticleIdList></Reference><Reference><Citation>Sica M, Roussel M, Legembre P. CD95/Fas stoichiometry in future precision medicine. Cell Death Different. (2025) 32:1570&#x2013;7. doi:&#xa0; 10.1038/s41418-025-01493-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-025-01493-9</ArticleId><ArticleId IdType="pmc">PMC12432253</ArticleId><ArticleId IdType="pubmed">40234610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjan K, Pathak C. Cellular dynamics of Fas-associated death domain in the regulation of cancer and inflammation. Int J Mol Sci. (2024) 25:3228. doi:&#xa0; 10.3390/ijms25063228, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25063228</ArticleId><ArticleId IdType="pmc">PMC10970579</ArticleId><ArticleId IdType="pubmed">38542202</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi M, Jackson SK, Macrae D, Shankar-Hari M, Tremoleda JL, Lilley E. Rethinking animal models of sepsis&#x2013;working towards improved clinical translation whilst integrating the 3Rs. Clin Sci. (2020) 134:1715&#x2013;34. doi:&#xa0; 10.1042/CS20200679, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20200679</ArticleId><ArticleId IdType="pmc">PMC7352061</ArticleId><ArticleId IdType="pubmed">32648582</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay MA, Schmidt EP, Bastarache JA, Calfee CS, Frevert CW, Martin TR. The translational value of rodent models of sepsis. Am J Respir Crit Care Med. (2024) 209:488&#x2013;90. doi:&#xa0; 10.1164/rccm.202308-1489VP, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202308-1489VP</ArticleId><ArticleId IdType="pmc">PMC10919117</ArticleId><ArticleId IdType="pubmed">38091521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamias G, Menghini P, Pizarro TT, Cominelli F. Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD. Gut. (2025) 74:652&#x2013;68. doi:&#xa0; 10.1136/gutjnl-2024-332504, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2024-332504</ArticleId><ArticleId IdType="pmc">PMC11885054</ArticleId><ArticleId IdType="pubmed">39266053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware CF, Croft M, Neil GA. Realigning the LIGHT signaling network to control dysregulated inflammation. J Exp Med. (2022) 219:e20220236. doi:&#xa0; 10.1084/jem.20220236, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220236</ArticleId><ArticleId IdType="pmc">PMC9130030</ArticleId><ArticleId IdType="pubmed">35604387</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P-C, Huang S-Y, Lin K-I, Hsieh S-L, Leu C-M. Suppression of NF-&#x3ba;B and downstream XBP1 by DcR3 contributes to a decrease in antibody secretion. J Immunol. (2025) 214:72&#x2013;84. doi:&#xa0; 10.1093/jimmun/vkae005, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jimmun/vkae005</ArticleId><ArticleId IdType="pubmed">40073262</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez Hern&#xe1;ndez G, Morell M, Alarc&#xf3;n-Riquelme ME. The role of BANK1 in B cell signaling and disease. Cells. (2021) 10:1184. doi:&#xa0; 10.3390/cells10051184, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10051184</ArticleId><ArticleId IdType="pmc">PMC8151866</ArticleId><ArticleId IdType="pubmed">34066164</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Wang S, Liao X, He Y, Qing Y. AB0112 Decoy receptor 3 and its signal pathway contribute to pathogenesis in ankylosing spondylitis. Ann Rheum Dis. (2022) 81:1186&#x2013;7. doi:&#xa0; 10.1136/annrheumdis-2022-eular.4408</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.4408</ArticleId></ArticleIdList></Reference><Reference><Citation>Haymour L, Jean M, Smulski C, Legembre P. CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways. Biochim Biophys Acta (BBA)-Rev Cancer. (2023) 1878:189004. doi:&#xa0; 10.1016/j.bbcan.2023.189004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2023.189004</ArticleId><ArticleId IdType="pubmed">37865305</ArticleId></ArticleIdList></Reference><Reference><Citation>Komorowski M, Salciccioli JD, Shalhoub J, Gordon AC, Marshall DC. Multinational trends in sepsis mortality between 1985 and 2019: a temporal analysis of the WHO Mortality Database. BMJ Open. (2024) 14:e074822. doi:&#xa0; 10.1136/bmjopen-2023-074822, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-074822</ArticleId><ArticleId IdType="pmc">PMC11404178</ArticleId><ArticleId IdType="pubmed">39266316</ArticleId></ArticleIdList></Reference><Reference><Citation>Prescott HC, Ostermann M. What is new and different in the 2021 Surviving Sepsis Campaign guidelines. Medizinische Klinik-Intensivmedizin und Notfallmedizin. (2023) 118:75&#x2013;9. doi:&#xa0; 10.1007/s00063-023-01028-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00063-023-01028-5</ArticleId><ArticleId IdType="pmc">PMC10246868</ArticleId><ArticleId IdType="pubmed">37286842</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer D, Deutschman CS, Hellman J, Myatra SN, Ostermann M, Prescott HC, et al. Surviving sepsis campaign research priorities 2023. Crit Care Med. (2024) 52:268&#x2013;96. doi:&#xa0; 10.1097/0000000000006135, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/0000000000006135</ArticleId><ArticleId IdType="pubmed">38240508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizera J, Bystro&#x144; A, Matuszewska K, Pilch J, Giordano U. Knowledge, management, and complications of sepsis and septic shock: A significant therapeutic challenge in the intensive care unit. J Acute Dis. (2024) 13:53&#x2013;9. doi:&#xa0; 10.4103/jad.jad_41_24</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jad.jad_41_24</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Huang S-Y, Sun J-H, Zhang H-C, Cai Q-L, Gao C, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Military Med Res. (2022) 9:56. doi:&#xa0; 10.1186/s40779-022-00422-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-022-00422-y</ArticleId><ArticleId IdType="pmc">PMC9547753</ArticleId><ArticleId IdType="pubmed">36209190</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy H, Javvaji CK, Malali S, Kumar S, Acharya S, Toshniwal S, et al. Navigating the cytokine storm: a comprehensive review of chemokines and cytokines in sepsis. Cureus. (2024) 16:e54275. doi:&#xa0; 10.7759/cureus.54275, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.54275</ArticleId><ArticleId IdType="pmc">PMC10944554</ArticleId><ArticleId IdType="pubmed">38496165</ArticleId></ArticleIdList></Reference><Reference><Citation>Addissouky TA, El Sayed IET, Ali MM, Wang Y, El Baz A, Khalil AA, et al. Molecular pathways in sepsis pathogenesis: Recent advances and therapeutic avenues. J Cell Immunol. (2024) 5:174&#x2013;83. doi:&#xa0; 10.33696/immunology.5.183</Citation><ArticleIdList><ArticleId IdType="doi">10.33696/immunology.5.183</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai V, Mathews G, Agrawal DK. Translational and clinical significance of DAMPs, PAMPs, and PRRs in trauma-induced inflammation. Arch Clin Biomed Res. (2022) 6:673. doi:&#xa0; 10.26502/acbr.50170279, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.26502/acbr.50170279</ArticleId><ArticleId IdType="pmc">PMC9491702</ArticleId><ArticleId IdType="pubmed">36147548</ArticleId></ArticleIdList></Reference><Reference><Citation>Arina P, Singer M. Pathophysiology of sepsis. Curr Opin Anesthesiol. (2021) 34:77&#x2013;84. doi:&#xa0; 10.1097/0000000000000963</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/0000000000000963</ArticleId><ArticleId IdType="pubmed">33652454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu CS, Wang W, Qiang X, Chen W, Lan X, Li J, et al. Endogenous regulation and pharmacological modulation of sepsis-induced HMGB1 release and action: An updated review. Cells. (2021) 10:2220. doi:&#xa0; 10.3390/cells10092220, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10092220</ArticleId><ArticleId IdType="pmc">PMC8469563</ArticleId><ArticleId IdType="pubmed">34571869</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al. NF-&#x3ba;B in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. (2024) 9:53. doi:&#xa0; 10.1038/s41392-024-01757-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01757-9</ArticleId><ArticleId IdType="pmc">PMC10910037</ArticleId><ArticleId IdType="pubmed">38433280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-&#x3ba;B signaling in inflammation and cancer. MedComm. (2021) 2:618&#x2013;53. doi:&#xa0; 10.1002/mco2.104, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.104</ArticleId><ArticleId IdType="pmc">PMC8706767</ArticleId><ArticleId IdType="pubmed">34977871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-&#x3ba;B pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. (2020) 5:209. doi:&#xa0; 10.1038/s41392-020-00312-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00312-6</ArticleId><ArticleId IdType="pmc">PMC7506548</ArticleId><ArticleId IdType="pubmed">32958760</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J-Y, Xiao J, Gao M, Zhou H-F, Fan H, Sun F, et al. IRF/Type I IFN signaling serves as a valuable therapeutic target in the pathogenesis of inflammatory bowel disease. Int Immunopharmacol. (2021) 92:107350. doi:&#xa0; 10.1016/j.intimp.2020.107350, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107350</ArticleId><ArticleId IdType="pubmed">33444921</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X, Tan S, Tan S. NLRP3 inflammasome in sepsis. Mol Med Rep. (2021) 24:514. doi:&#xa0; 10.3892/mmr.2021.12153, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2021.12153</ArticleId><ArticleId IdType="pubmed">33982766</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigneron C, Py BF, Monneret G, Venet F. The double sides of NLRP3 inflammasome activation in sepsis. Clin Sci. (2023) 137:333&#x2013;51. doi:&#xa0; 10.1042/20220556, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/20220556</ArticleId><ArticleId IdType="pubmed">36856019</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch K, Kny M, Huang N, Klassert TE, Stock M, Hahn A, et al. Inhibition of the NLRP3/IL-1&#x3b2; axis protects against sepsis-induced cardiomyopathy. J Cachexia Sarcopenia Muscle. (2021) 12:1653&#x2013;68. doi:&#xa0; 10.1002/jcsm.12763, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12763</ArticleId><ArticleId IdType="pmc">PMC8718055</ArticleId><ArticleId IdType="pubmed">34472725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, Jin S, Tian W, Zhang Y, Xu L, Zhang T, et al. Role of caspase-1/caspase-11-hmgb1-rage/tlr4 signaling in the exacerbation of extrapulmonary sepsis induced lung injury by mechanical ventilation. Shock. (2023) 10:1097. doi:&#xa0; 10.1097/SHK.0000000000002471, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000002471</ArticleId><ArticleId IdType="pubmed">39228020</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Ju C, Au K, Zhu J, Zhao B, Shang Y, et al. Engagement of TLR and dectin-1/Syk signaling Is required for activation of Notch targets in dendritic cells. Infect Microbes Dis. (2021) 3:101&#x2013;8. doi:&#xa0; 10.1097/9.0000000000000053</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/9.0000000000000053</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Chen Y, Ma J, Zhou W, Wang Y, Wang Y, et al. Role and mechanism of the Dectin-1-mediated Syk/NF-&#x3ba;B signaling pathway in Talaromyces marneffei infection. Exp Ther Med. (2022) 23:84. doi:&#xa0; 10.3892/etm.2021.11007, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.11007</ArticleId><ArticleId IdType="pmc">PMC8688926</ArticleId><ArticleId IdType="pubmed">34938366</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao M, Wang G, Xie J. Immune dysregulation in sepsis: experiences, lessons and perspectives. Cell Death Discov. (2023) 9:465. doi:&#xa0; 10.1038/s41420-023-01766-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-023-01766-7</ArticleId><ArticleId IdType="pmc">PMC10730904</ArticleId><ArticleId IdType="pubmed">38114466</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J, Zhou L, Tian W, Liu X, Yang L, Yang X, et al. Deep insight into cytokine storm: from pathogenesis to treatment. Signal Transduct Targeted Ther. (2025) 10:112. doi:&#xa0; 10.1038/s41392-025-02178-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-025-02178-y</ArticleId><ArticleId IdType="pmc">PMC12000524</ArticleId><ArticleId IdType="pubmed">40234407</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Qiao X, Yin J, Kong J, Han W, Qin J, et al. Advancements in omics technologies: Molecular mechanisms of acute lung injury and acute respiratory distress syndrome. Int J Mol Med. (2024) 55:38. doi:&#xa0; 10.3892/ijmm.2024.5479, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2024.5479</ArticleId><ArticleId IdType="pmc">PMC11722059</ArticleId><ArticleId IdType="pubmed">39749711</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao X, Yin J, Zheng Z, Li L, Feng X. Endothelial cell dynamics in sepsis-induced acute lung injury and acute respiratory distress syndrome: pathogenesis and therapeutic implications. Cell Commun Signaling. (2024) 22:241. doi:&#xa0; 10.1186/s12964-024-01620-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-024-01620-y</ArticleId><ArticleId IdType="pmc">PMC11046830</ArticleId><ArticleId IdType="pubmed">38664775</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolmatova EV, Wang K, Mandavilli R, Griendling KK. The effects of sepsis on endothelium and clinical implications. Cardiovasc Res. (2021) 117:60&#x2013;73. doi:&#xa0; 10.1093/cvr/cvaa070, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa070</ArticleId><ArticleId IdType="pmc">PMC7810126</ArticleId><ArticleId IdType="pubmed">32215570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ari MM, Amini ME, Sholeh M, Bialvaei AZ. The effect of polyclonal and monoclonal based antibodies as promising potential therapy for treatment of sepsis: A systematic review. New Microbes New Infect. (2024) 60:101435. doi:&#xa0; 10.1016/j.nmni.2024.101435, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmni.2024.101435</ArticleId><ArticleId IdType="pmc">PMC11163170</ArticleId><ArticleId IdType="pubmed">38860003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitre T, Drover K, Chaudhuri D, Zeraaktkar D, Menon K, Gershengorn HB, et al. Corticosteroids in sepsis and septic shock: a systematic review, pairwise, and dose-response meta-analysis. Crit Care Explorations. (2024) 6:e1000. doi:&#xa0; 10.1097/0000000000001000, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/0000000000001000</ArticleId><ArticleId IdType="pmc">PMC10798738</ArticleId><ArticleId IdType="pubmed">38250247</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J-Q, Zhang W-Y, Fu J-J, Fang X-Z, Gao C-G, Li C, et al. Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations. Military Med Res. (2024) 11:78. doi:&#xa0; 10.1186/s40779-024-00581-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-024-00581-0</ArticleId><ArticleId IdType="pmc">PMC11648306</ArticleId><ArticleId IdType="pubmed">39676169</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X, Liu Z, Wang Y. Advances in the study of immunosuppressive mechanisms in sepsis. J Inflammation Res. (2023) 16:3967&#x2013;81. doi:&#xa0; 10.2147/426007, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/426007</ArticleId><ArticleId IdType="pmc">PMC10497210</ArticleId><ArticleId IdType="pubmed">37706064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Zhang W, Chen L, Lu X, Tu Y. Lymphopenia in sepsis: a narrative review. Crit Care. (2024) 28:315. doi:&#xa0; 10.1186/s13054-024-05099-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-024-05099-4</ArticleId><ArticleId IdType="pmc">PMC11414153</ArticleId><ArticleId IdType="pubmed">39304908</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S, Liu X, Chen L, Wu X, Tao L, Pan X, et al. Fas/FasL mediates NF-&#x3ba;Bp65/PUMA-modulated hepatocytes apoptosis via autophagy to drive liver fibrosis. Cell Death Dis. (2021) 12:474. doi:&#xa0; 10.1038/s41419-021-03749-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03749-x</ArticleId><ArticleId IdType="pmc">PMC8115181</ArticleId><ArticleId IdType="pubmed">33980818</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X, Tu H, Bai X, Qin S, Li Z. Intrinsic/extrinsic apoptosis and pyroptosis contribute to the selective depletion of B cell subsets in septic shock patients. Shock. (2023) 60:345&#x2013;53. doi:&#xa0; 10.1097/0000000000002174, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/0000000000002174</ArticleId><ArticleId IdType="pmc">PMC10510799</ArticleId><ArticleId IdType="pubmed">37477437</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu M, Wang Y, Qiu Z, Zhu S, Guo K, Chen W, et al. Necroptosis, pyroptosis, ferroptosis in sepsis and treatment. Shock. (2022) 57:161&#x2013;71. doi:&#xa0; 10.1097/0000000000001936, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/0000000000001936</ArticleId><ArticleId IdType="pubmed">35759299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L-Y, Duan Y, He P-Y, Wu M-Y, Wei S-T, Du X-H, et al. Dysregulated dendritic cells in sepsis: functional impairment and regulated cell death. Cell Mol Biol Lett. (2024) 29:81. doi:&#xa0; 10.1186/s11658-024-00602-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11658-024-00602-9</ArticleId><ArticleId IdType="pmc">PMC11140885</ArticleId><ArticleId IdType="pubmed">38816685</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng R-M, Huang G, Wang T, Zhou J. Regulated programmed cell death in sepsis associated acute lung injury: From pathogenesis to therapy. Int Immunopharmacol. (2025) 148:114111. doi:&#xa0; 10.1016/j.intimp.2025.114111, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2025.114111</ArticleId><ArticleId IdType="pubmed">39832461</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansari MA, Das S, Rai G, Singh PK, Lahan S, Tyagi A, et al. Low monocytic HLA-DR expression in critically ill patients of sepsis: an indicator for antimicrobial and/or immunomodulatory intervention. Transplant Immunology (2023) 81:101942. doi:&#xa0; 10.1016/j.trim.2023.101942, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trim.2023.101942</ArticleId><ArticleId IdType="pubmed">37866671</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Cai W, Zhang L, Wu Y, Huang Y, Zhao W. Decreased monocytic HLA-DR in patients with sepsis: Prediction of diagnosis, severity and prognosis. Clin Biochem. (2025) 135:110851. doi:&#xa0; 10.1016/j.clinbiochem.2024.110851, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2024.110851</ArticleId><ArticleId IdType="pubmed">39550023</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch LM, Sun J, Eichacker PQ, Torabi-Parizi P. Inhibitory immune checkpoint molecule expression in clinical sepsis studies: a systematic review. Crit Care Med. (2020) 48:1365&#x2013;74. doi:&#xa0; 10.1097/CCM.0000000000004496, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004496</ArticleId><ArticleId IdType="pmc">PMC10878494</ArticleId><ArticleId IdType="pubmed">32706554</ArticleId></ArticleIdList></Reference><Reference><Citation>McCulloch TR, Rossi GR, Miranda-Hernandez S, Valencia-Hernandez AM, Alim L, Belle CJ, et al. The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy. Immunol Cell Biol. (2024) 102:721&#x2013;33. doi:&#xa0; 10.1111/imcb.12794, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12794</ArticleId><ArticleId IdType="pubmed">38873699</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J-F, Wang Y-P, Xie J, Zhao Z-Z, Gupta S, Guo Y, et al. Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis. Blood J Am Soc Hematol. (2021) 138:806&#x2013;10. doi:&#xa0; 10.1182/blood.2020009417, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020009417</ArticleId><ArticleId IdType="pubmed">34473230</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier T, Yao C, Dowdy T, Jin W, Lim Y-J, Pati&#xf1;o LC, et al. TGF-&#x3b2; uncouples glycolysis and inflammation in macrophages and controls survival during sepsis. Sci Signaling. (2023) 16:eade0385. doi:&#xa0; 10.1126/scisignal.ade0385, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.ade0385</ArticleId><ArticleId IdType="pmc">PMC11145950</ArticleId><ArticleId IdType="pubmed">37552767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MJ, Bae J, Lee JH, Park YJ, Lee HAR, Mun S, et al. Serial change of endotoxin tolerance in a polymicrobial sepsis model. Int J Mol Sci. (2022) 23:6581. doi:&#xa0; 10.3390/ijms23126581, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23126581</ArticleId><ArticleId IdType="pmc">PMC9223582</ArticleId><ArticleId IdType="pubmed">35743025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranzani O, Annane D, Singer M. Fludrocortisone with hydrocortisone in sepsis: new evidence in an ongoing debate. Intensive Care Med. (2024) 50:2138&#x2013;40. doi:&#xa0; 10.1007/s00134-024-07699-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-024-07699-8</ArticleId><ArticleId IdType="pubmed">39531050</ArticleId></ArticleIdList></Reference><Reference><Citation>Heming N, Renault A, Kuperminc E, Brun-Buisson C, Megarbane B, Quenot J-P, et al. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med. (2024) 12:366&#x2013;74. doi:&#xa0; 10.1016/-2600(23)00430-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/-2600(23)00430-7</ArticleId><ArticleId IdType="pubmed">38310918</ArticleId></ArticleIdList></Reference><Reference><Citation>Gander-Bui HTT, Schl&#xe4;fli J, Baumgartner J, Walthert S, Genitsch V, van Geest G, et al. Targeted removal of macrophage-secreted interleukin-1 receptor antagonist protects against lethal Candida albicans sepsis. Immunity. (2023) 56:1743&#x2013;60. doi:&#xa0; 10.1016/j.immuni.2023.06.023, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2023.06.023</ArticleId><ArticleId IdType="pubmed">37478856</ArticleId></ArticleIdList></Reference><Reference><Citation>Slim MA, van Mourik N, Bakkerus L, Fuller K, Acharya L, Giannidis T, et al. Towards personalized medicine: a scoping review of immunotherapy in sepsis. Crit Care. (2024) 28:183. doi:&#xa0; 10.1186/s13054-024-04964-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-024-04964-6</ArticleId><ArticleId IdType="pmc">PMC11134696</ArticleId><ArticleId IdType="pubmed">38807151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu X, Liu K, Li H, Wang F-S, Xu R. Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19. Cell Mol Immunol. (2021) 18:2057&#x2013;8. doi:&#xa0; 10.1038/s41423-021-00719-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00719-3</ArticleId><ArticleId IdType="pmc">PMC8287545</ArticleId><ArticleId IdType="pubmed">34282298</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacheron C-H, Lepape A, Venet F, Monneret G, Gueyffier F, Boutitie F, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: the GRID randomized controlled trial. J Crit Care. (2023) 78:154330. doi:&#xa0; 10.1016/j.jcrc.2023.154330, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2023.154330</ArticleId><ArticleId IdType="pubmed">37267804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo G, Samal D, Khandayataray P, Murthy MK. A review on caspases: key regulators of biological activities and apoptosis. Mol Neurobiol. (2023) 60:5805&#x2013;37. doi:&#xa0; 10.1007/s12035-023-03433-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-023-03433-5</ArticleId><ArticleId IdType="pubmed">37349620</ArticleId></ArticleIdList></Reference><Reference><Citation>Magri Z, Jetton D, Muendlein HI, Connolly WM, Russell H, Smirnova I, et al. CD14 is a decision-maker between Fas-mediated death and inflammation. Cell Rep. (2024) 43:114685. doi:&#xa0; 10.1016/j.celrep.2024.114685, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2024.114685</ArticleId><ArticleId IdType="pmc">PMC11471008</ArticleId><ArticleId IdType="pubmed">39213151</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzyzowska M, Patrycy M, Chodkowski M, Janicka M, Kowalczyk A, Skulska K, et al. Fas/fasL-mediated apoptosis and inflammation contribute to recovery from HSV-2-mediated spinal cord infection. Viruses. (2024) 16:1363. doi:&#xa0; 10.3390/v16091363, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16091363</ArticleId><ArticleId IdType="pmc">PMC11436029</ArticleId><ArticleId IdType="pubmed">39339840</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Weng L, Wu X, Du B. The role of programmed cell death in organ dysfunction induced by opportunistic pathogens. Crit Care. (2025) 29:43. doi:&#xa0; 10.1186/s13054-025-05278-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-025-05278-x</ArticleId><ArticleId IdType="pmc">PMC11761187</ArticleId><ArticleId IdType="pubmed">39856779</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi Y, Munesue S, Saeki M, Harashima A, Kimura K, Oshima Y, et al. Platelet aggregation elicits FasL expression and hepatocyte apoptosis in sinusoidal obstruction syndrome. Sci Rep. (2025) 15:18859. doi:&#xa0; 10.1038/s41598-025-03839-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-025-03839-2</ArticleId><ArticleId IdType="pmc">PMC12122828</ArticleId><ArticleId IdType="pubmed">40442395</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao Z, Ma Y, Wang Y, Liu T, Zhang Q, Liu X, et al. Protective effect of adipose-derived mesenchymal stem cell secretome against hepatocyte apoptosis induced by liver ischemia-reperfusion with partial hepatectomy injury. Stem Cells Int. (2021) 2021:9969372. doi:&#xa0; 10.1155/2021/9969372, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/9969372</ArticleId><ArticleId IdType="pmc">PMC8390152</ArticleId><ArticleId IdType="pubmed">34457008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, Zhu Y, Peng S, Miao Y, Lu Q, Zhang L, et al. TP induces hepatic intolerance to FasL-mediated hepatocyte apoptosis by inhibiting XIAP. Toxicol Lett. (2023) 390:25&#x2013;32. doi:&#xa0; 10.1016/j.toxlet.2023.11.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxlet.2023.11.001</ArticleId><ArticleId IdType="pubmed">37944651</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Zhu Y, Fang Z, Geng M, Zhang J, Zheng Y, et al. Fish requires FasL to facilitate CD8+ T-cell function and antimicrobial immunity. J Immunol. (2025) 214:1219&#x2013;35. doi:&#xa0; 10.1093/jimmun/vkaf022, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jimmun/vkaf022</ArticleId><ArticleId IdType="pubmed">40073091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente L, Mart&#xed;n MM, Ortiz-L&#xf3;pez R, Gonz&#xe1;lez-Rivero AF, Gonz&#xe1;lez-Mesa A, Villacampa-Jim&#xe9;nez JJ, et al. Serum Fas levels during first week of sepsis are associated with severity and mortality. Expert Rev Mol Diagn. (2023) 23:181&#x2013;5. doi:&#xa0; 10.1080/14737159.2023.2179876, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2023.2179876</ArticleId><ArticleId IdType="pubmed">36779960</ArticleId></ArticleIdList></Reference><Reference><Citation>Suo F, Zhou X, Setroikromo R, Quax WJ. Receptor specificity engineering of TNF superfamily ligands. Pharmaceutics. (2022) 14:181. doi:&#xa0; 10.3390/pharmaceutics14010181, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14010181</ArticleId><ArticleId IdType="pmc">PMC8781899</ArticleId><ArticleId IdType="pubmed">35057080</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal T, Gaur H, Wamba BE, Michalak AG, Stout C, Watson MR, et al. Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer. Cell Death Different. (2023) 30:2408&#x2013;31. doi:&#xa0; 10.1038/s41418-023-01229-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-023-01229-7</ArticleId><ArticleId IdType="pmc">PMC10657439</ArticleId><ArticleId IdType="pubmed">37838774</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajabi S, Maresca M, Yumashev AV, Choopani R, Hajimehdipoor H. The most competent plant-derived natural products for targeting apoptosis in cancer therapy. Biomolecules. (2021) 11:534. doi:&#xa0; 10.3390/biom11040534, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11040534</ArticleId><ArticleId IdType="pmc">PMC8066452</ArticleId><ArticleId IdType="pubmed">33916780</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Lu Y, Zheng J, Liu X. Of mice and men: Laboratory murine models for recapitulating the immunosuppression of human sepsis. Front Immunol. (2022) 13:956448. doi:&#xa0; 10.3389/fimmu.2022.956448, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.956448</ArticleId><ArticleId IdType="pmc">PMC9388785</ArticleId><ArticleId IdType="pubmed">35990662</ArticleId></ArticleIdList></Reference><Reference><Citation>Magerus A, Bercher-Brayer C, Rieux-Laucat F. The genetic landscape of the FAS pathway deficiencies. Biomed J. (2021) 44:388&#x2013;99. doi:&#xa0; 10.1016/j.bj.2021.06.005, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2021.06.005</ArticleId><ArticleId IdType="pmc">PMC8514852</ArticleId><ArticleId IdType="pubmed">34171534</ArticleId></ArticleIdList></Reference><Reference><Citation>Casamayor-Polo L, L&#xf3;pez-Nevado M, Paz-Artal E, Anel A, Rieux-Laucat F, Allende LM. Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS). Crit Rev Clin Lab Sci. (2021) 58:253&#x2013;74. doi:&#xa0; 10.1080/10408363.2020.1855623, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408363.2020.1855623</ArticleId><ArticleId IdType="pubmed">33356695</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada A, Arakaki R, Saito M, Kudo Y, Ishimaru N. Dual role of Fas/FasL-mediated signal in peripheral immune tolerance. Front Immunol. (2017) 8:403. doi:&#xa0; 10.3389/fimmu.2017.00403, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00403</ArticleId><ArticleId IdType="pmc">PMC5380675</ArticleId><ArticleId IdType="pubmed">28424702</ArticleId></ArticleIdList></Reference><Reference><Citation>Manresa MC, Wu A, Nhu QM, Chiang AW, Okamoto K, Miki H, et al. LIGHT controls distinct homeostatic and inflammatory gene expression profiles in esophageal fibroblasts via differential HVEM and LT&#x3b2;R-mediated mechanisms. Mucosal Immunol. (2022) 15:327&#x2013;37. doi:&#xa0; 10.1038/s41385-021-00472-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-021-00472-w</ArticleId><ArticleId IdType="pmc">PMC8866113</ArticleId><ArticleId IdType="pubmed">34903876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta RK, Figueroa DS, Fung K, Miki H, Miller J, Ay F, et al. Light signaling through lt&#x3b2;r and hvem in keratinocytes promotes psoriasis and atopic dermatitis-like skin inflammation. J Autoimmun. (2024) 144:103177. doi:&#xa0; 10.1016/j.jaut.2024.103177, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2024.103177</ArticleId><ArticleId IdType="pmc">PMC12406946</ArticleId><ArticleId IdType="pubmed">38368767</ArticleId></ArticleIdList></Reference><Reference><Citation>Piao W, Kasinath V, Saxena V, Lakhan R, Iyyathurai J, Bromberg JS. LT&#x3b2;R signaling controls lymphatic migration of immune cells. Cells. (2021) 10:747. doi:&#xa0; 10.3390/cells10040747, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10040747</ArticleId><ArticleId IdType="pmc">PMC8065509</ArticleId><ArticleId IdType="pubmed">33805271</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuptrine CW, Perez VM, Selitsky SR, Schreiber TH, Fromm G. Shining a LIGHT on myeloid cell targeted immunotherapy. Eur J Cancer. (2023) 187:147&#x2013;60. doi:&#xa0; 10.1016/j.ejca.2023.03.040, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2023.03.040</ArticleId><ArticleId IdType="pubmed">37167762</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Zhu C, Liao Y, Zhou M, Xu W, Zou Z. Caspase-8 in inflammatory diseases: a potential therapeutic target. Cell Mol Biol Lett. (2024) 29:130. doi:&#xa0; 10.1186/s11658-024-00646-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11658-024-00646-x</ArticleId><ArticleId IdType="pmc">PMC11463096</ArticleId><ArticleId IdType="pubmed">39379817</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;pner S, Raykova A, Radpour R, Amrein M, Koller D, Baerlocher G, et al. LIGHT/LT&#x3b2;R signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. Nat Commun. (2021) 12:1065. doi:&#xa0; 10.1038/s41467-021-21317-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21317-x</ArticleId><ArticleId IdType="pmc">PMC7887212</ArticleId><ArticleId IdType="pubmed">33594067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z, et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct Targeted Ther. (2024) 9:225. doi:&#xa0; 10.1038/s41392-024-01947-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01947-5</ArticleId><ArticleId IdType="pmc">PMC11358547</ArticleId><ArticleId IdType="pubmed">39198425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielecki P, Gindzienska-Sieskiewicz E, Resze&#x107; J, Piszczatowski B, Rogowski M, Kowal-Bielecka O, et al. Expression of LIGHT/TNFSF14 and its receptors, HVEM and LT&#x3b2;R, correlates with the severity of fibrosis in lacrimal sacs from patients with lacrimal duct obstruction. Ophthalmol Ther. (2021) 10:63&#x2013;74. doi:&#xa0; 10.1007/s40123-020-00320-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40123-020-00320-3</ArticleId><ArticleId IdType="pmc">PMC7665092</ArticleId><ArticleId IdType="pubmed">33188486</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousa RS, Invernizzi P, Jones JL, Mousa HS. TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD. Front Immunol. (2025) 16:1657071. doi:&#xa0; 10.3389/fimmu.2025.1657071, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2025.1657071</ArticleId><ArticleId IdType="pmc">PMC12477249</ArticleId><ArticleId IdType="pubmed">41030453</ArticleId></ArticleIdList></Reference><Reference><Citation>Tettoni E, Gabbiadini R, Dal Buono A, Privitera G, Vadal&#xe0; V, Migliorisi G, et al. TL1A as a target in inflammatory bowel disease: exploring mechanisms and therapeutic potential. Int J Mol Sci. (2025) 26:5017. doi:&#xa0; 10.3390/ijms26115017, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms26115017</ArticleId><ArticleId IdType="pmc">PMC12154025</ArticleId><ArticleId IdType="pubmed">40507829</ArticleId></ArticleIdList></Reference><Reference><Citation>Feoktistova M, Makarov R, Yazdi AS, Panayotova-Dimitrova D. RIPK1 and TRADD regulate TNF-induced signaling and ripoptosome formation. Int J Mol Sci. (2021) 22:12459. doi:&#xa0; 10.3390/ijms222212459, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212459</ArticleId><ArticleId IdType="pmc">PMC8617695</ArticleId><ArticleId IdType="pubmed">34830347</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Jiang P, Sun P, Su N, Lin F. Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation. Exp Ther Med. (2021) 22:693. doi:&#xa0; 10.3892/etm.2021.10125, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10125</ArticleId><ArticleId IdType="pmc">PMC8111866</ArticleId><ArticleId IdType="pubmed">33986858</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Xiu Q, Min Q, Cheng X, Xiao H, Jia Z, et al. TL1A induces apoptosis via DR3 in grass carp (Ctenopharyngodon idella). Fish Shellfish Immunol Rep. (2023) 4:100090. doi:&#xa0; 10.1016/j.fsirep.2023.100090, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fsirep.2023.100090</ArticleId><ArticleId IdType="pmc">PMC10033717</ArticleId><ArticleId IdType="pubmed">36970231</ArticleId></ArticleIdList></Reference><Reference><Citation>Varricchi G, Poto R, Criscuolo G, Strisciuglio C, Nair P, Marone G. TL1A: a novel alarmin in airway, intestinal, and autoimmune disorders. J Allergy Clin Immunol. (2025) 155:1420&#x2013;34. doi:&#xa0; 10.1016/j.jaci.2025.02.018, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2025.02.018</ArticleId><ArticleId IdType="pubmed">40010414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Zhang D, Pan Y, Liu X, Xu J, Qiao X, et al. The TL1A-DR3 axis in asthma: membrane-bound and secreted TL1A co-determined the development of airway remodeling. Allergy Asthma Immunol Res. (2022) 14:233. doi:&#xa0; 10.4168/aair.2022.14.2.233, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4168/aair.2022.14.2.233</ArticleId><ArticleId IdType="pmc">PMC8914606</ArticleId><ArticleId IdType="pubmed">35255540</ArticleId></ArticleIdList></Reference><Reference><Citation>Menghini P, Butt&#xf3; LF, Gomez-Nguyen A, Aladyshkina N, Buela K-A, Osme A, et al. TL1A/DR3 signaling regulates the generation of pathogenic Th9 cells in experimental inflammatory bowel disease. bioRxiv. (2024) 02:9. doi:&#xa0; 10.1101/2024.02.09.57968</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.02.09.57968</ArticleId></ArticleIdList></Reference><Reference><Citation>Valatas V, Kolios G, Bamias G. TL1A (TNFSF15) and DR3 (TNFRSF25): a co-stimulatory system of cytokines with diverse functions in gut mucosal immunity. Front Immunol. (2019) 10:583. doi:&#xa0; 10.3389/fimmu.2019.00583, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00583</ArticleId><ArticleId IdType="pmc">PMC6445966</ArticleId><ArticleId IdType="pubmed">30972074</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng F, Jiang X, Wang X, Zheng Q, Wang XN, Mei C, et al. Tumor necrosis factor&#x2013;like cytokine 1A plays a role in inflammatory bowel disease pathogenesis. Proc Natl Acad Sci. (2023) 120:e2120771120. doi:&#xa0; 10.1073/pnas.2120771120, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2120771120</ArticleId><ArticleId IdType="pmc">PMC10452302</ArticleId><ArticleId IdType="pubmed">37579137</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Zhang J, Zhang J, Ji X, Qi Q, Xu J, et al. Identification of a novel role for TL1A/DR3 deficiency in acute respiratory distress syndrome that exacerbates alveolar epithelial disruption. Respir Res. (2023) 24:182. doi:&#xa0; 10.1186/s12931-023-02488-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-023-02488-1</ArticleId><ArticleId IdType="pmc">PMC10334539</ArticleId><ArticleId IdType="pubmed">37434162</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhang J, Zhang D, Pan Y, Zeng R, Xu C, et al. Necroptosis plays a role in TL1A-induced airway inflammation and barrier damage in asthma. Respir Res. (2024) 25:271. doi:&#xa0; 10.1186/s12931-024-02900-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-024-02900-4</ArticleId><ArticleId IdType="pmc">PMC11238433</ArticleId><ArticleId IdType="pubmed">38987753</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Shi W, Sun H, Ji Y, Chen Y, Guo X, et al. Activation of DR3 signaling causes loss of ILC3s and exacerbates intestinal inflammation. Nat Commun. (2019) 10:3371. doi:&#xa0; 10.1038/s41467-019-11304-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11304-8</ArticleId><ArticleId IdType="pmc">PMC6662828</ArticleId><ArticleId IdType="pubmed">31358760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwolak A, Chan SR, Harvilla P, Mahady S, Armstrong AA, Luistro L, et al. A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3. Sci Rep. (2022) 12:20538. doi:&#xa0; 10.1038/s41598-022-24984-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-24984-y</ArticleId><ArticleId IdType="pmc">PMC9709071</ArticleId><ArticleId IdType="pubmed">36446890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Xia D, You Y, Cheng Y, Bai B, Feng G, et al. Effects of dioscin from Dioscorea nipponica on TL1A/DR3 and Th9 cells in a collagen-induced arthritis mouse model. Int Immunopharmacol. (2025) 147:114028. doi:&#xa0; 10.1016/j.intimp.2025.114028, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2025.114028</ArticleId><ArticleId IdType="pubmed">39798473</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Fu L, Zhou P, Lu Y, Zhang L, Wang W, et al. Effects of tumor necrosis factor-like ligand 1A (TL1A) on imiquimod-induced psoriasiform skin inflammation in mice. Arch Dermatol Res. (2020) 312:481&#x2013;90. doi:&#xa0; 10.1007/s00403-019-02030-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00403-019-02030-8</ArticleId><ArticleId IdType="pubmed">31953572</ArticleId></ArticleIdList></Reference><Reference><Citation>Solitano V, Jairath V, Ungaro F, Peyrin-Biroulet L, Danese S. TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis. Med. (2024) 5:386&#x2013;400. doi:&#xa0; 10.1016/j.medj.2024.03.010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2024.03.010</ArticleId><ArticleId IdType="pubmed">38574740</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu N-L, Huang D-Y, Hsieh S-L, Dai Y-S, Lin W-W. Decoy receptor 3 is involved in epidermal keratinocyte commitment to terminal differentiation via EGFR and PKC activation. Exp Mol Med. (2022) 54:542&#x2013;51. doi:&#xa0; 10.1038/s12276-022-00762-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00762-8</ArticleId><ArticleId IdType="pmc">PMC9076855</ArticleId><ArticleId IdType="pubmed">35478210</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Liao X, Wang S, He Y, Qing Y. POS0349 Decoy receptor 3 and its signal pathway contribute to pathogenesis in primary gouty arthritis. Ann Rheum Dis. (2022) 81:428. doi:&#xa0; 10.1136/annrheumdis-2022-eular.3540</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.3540</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y-J, Peng C-T, Lin Y-H, Lin G-J, Huang S-H, Chen S-J, et al. Decoy receptor 3 promotes preosteoclast cell death via reactive oxygen species-induced fas ligand expression and the IL-1&#x3b1;/IL-1 receptor antagonist pathway. Mediators Inflamm. (2020) 1):1237281. doi:&#xa0; 10.1155/2020/1237281, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/1237281</ArticleId><ArticleId IdType="pmc">PMC7303756</ArticleId><ArticleId IdType="pubmed">32587467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Brown NK, Wang B, Shariati K, Wang K, Fuchs S, et al. Local immunomodulatory strategies to prevent allo-rejection in transplantation of insulin-producing cells. Adv Sci. (2021) 8:2003708. doi:&#xa0; 10.1002/advs.202003708, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202003708</ArticleId><ArticleId IdType="pmc">PMC8425879</ArticleId><ArticleId IdType="pubmed">34258870</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Lianoglou S, Sandmann T, Calvert M, Suh JH, Thomsen E, et al. Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. Mol Neurodegen. (2022) 17:41. doi:&#xa0; 10.1186/s13024-022-00547-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00547-7</ArticleId><ArticleId IdType="pmc">PMC9188195</ArticleId><ArticleId IdType="pubmed">35690868</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal AF, Herreno-Pach&#xf3;n AM, Benincore-Fl&#xf3;rez E, Karunathilaka A, Tomatsu S. Current strategies for increasing knock-in efficiency in CRISPR/Cas9-based approaches. Int J Mol Sci. (2024) 25:2456. doi:&#xa0; 10.3390/ijms25052456, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25052456</ArticleId><ArticleId IdType="pmc">PMC10931195</ArticleId><ArticleId IdType="pubmed">38473704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Oh H-K, Choi BS, Lee HH, Lee KJ, Kim UG, et al. Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia. Mol Ther Nucleic Acids. (2022) 29:551&#x2013;62. doi:&#xa0; 10.1016/j.omtn.2022.08.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2022.08.002</ArticleId><ArticleId IdType="pmc">PMC9403902</ArticleId><ArticleId IdType="pubmed">36090746</ArticleId></ArticleIdList></Reference><Reference><Citation>Han R, Su L, Cheng L. Advancing human vaccine development using humanized mouse models. Vaccines. (2024) 12:1012. doi:&#xa0; 10.3390/vaccines12091012, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12091012</ArticleId><ArticleId IdType="pmc">PMC11436046</ArticleId><ArticleId IdType="pubmed">39340042</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez DP, Jiang S, Wood J, Wang R, Hall CM, Peerboom C, et al. Knock-in models related to Alzheimer&#x2019;s disease: synaptic transmission, plaques and the role of microglia. Mol Neurodegen. (2021) 16:47. doi:&#xa0; 10.1186/s13024-021-00457-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00457-0</ArticleId><ArticleId IdType="pmc">PMC8281661</ArticleId><ArticleId IdType="pubmed">34266459</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Swidnicka-Siergiejko AK, Daniluk J, Gaiser S, Yao Y, Peng L, et al. Transgenic expression of PRSS1R122H sensitizes mice to pancreatitis. Gastroenterology. (2020) 158:1072&#x2013;82.e7. doi:&#xa0; 10.1053/j.gastro.2019.08.016, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.08.016</ArticleId><ArticleId IdType="pmc">PMC7580257</ArticleId><ArticleId IdType="pubmed">31419436</ArticleId></ArticleIdList></Reference><Reference><Citation>Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. (2021) 20:309&#x2013;25. doi:&#xa0; 10.1038/s41573-020-00135-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-00135-8</ArticleId><ArticleId IdType="pubmed">33536635</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shemi AG, Alqurashi A, Abdulrahman JA, Alzahrani HD, Almwalad KS, Felfilan HH, et al. IL-10-Directed cancer immunotherapy: Preclinical advances, clinical insights, and future perspectives. Cancers. (2025) 17:1012. doi:&#xa0; 10.3390/cancers17061012, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers17061012</ArticleId><ArticleId IdType="pmc">PMC11940594</ArticleId><ArticleId IdType="pubmed">40149345</ArticleId></ArticleIdList></Reference><Reference><Citation>Deckers J, Anbergen T, Hokke AM, de Dreu A, Schrijver DP, de Bruin K, et al. Engineering cytokine therapeutics. Nat Rev Bioeng. (2023) 1:286&#x2013;303. doi:&#xa0; 10.1038/s44222-023-00030-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44222-023-00030-y</ArticleId><ArticleId IdType="pmc">PMC9933837</ArticleId><ArticleId IdType="pubmed">37064653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Wang G, Zhang Z, Liang X, Wang G, Xu M, et al. Locally administered liposomal drug depot enhances rheumatoid arthritis treatment by inhibiting inflammation and promoting cartilage repair. J Nanobiotechnol. (2025) 23:69. doi:&#xa0; 10.1186/s12951-025-03110-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-025-03110-w</ArticleId><ArticleId IdType="pmc">PMC11783794</ArticleId><ArticleId IdType="pubmed">39891123</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L, Dai Y, Xu Y, Sun H, Gao H, Hao H, et al. Dual responsive magnetic DCR3 nanoparticles: A new strategy for efficiently targeting hepatocellular carcinoma. Small. (2025) 21:2402909. doi:&#xa0; 10.1002/smll.202402909, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.202402909</ArticleId><ArticleId IdType="pubmed">39604254</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Tu X, Guo J, Zheng J, Liao X, He Y, et al. DcR3 suppresses the NF-&#x3ba;B pathway and the NLRP3 inflammasome activation in gouty inflammation. Chin Med J. (2024) 137:2644&#x2013;6. doi:&#xa0; 10.1097/CM9.0000000000003274, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000003274</ArticleId><ArticleId IdType="pmc">PMC11557038</ArticleId><ArticleId IdType="pubmed">39294866</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzer MC, Bludau I, Stafford CA, Hornung V, Mann M. Phosphoproteome profiling uncovers a key role for CDKs in TNF signaling. Nat Commun. (2021) 12:6053. doi:&#xa0; 10.1038/s41467-021-26289-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26289-6</ArticleId><ArticleId IdType="pmc">PMC8523534</ArticleId><ArticleId IdType="pubmed">34663829</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Yang X, Dai Y, Zhao Z, Zhu J, Guo H, et al. Single-cell sequencing to multi-omics: technologies and applications. biomark Res. (2024) 12:110. doi:&#xa0; 10.1186/s40364-024-00643-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40364-024-00643-4</ArticleId><ArticleId IdType="pmc">PMC11438019</ArticleId><ArticleId IdType="pubmed">39334490</ArticleId></ArticleIdList></Reference><Reference><Citation>Muneer G, Chen CS, Chen YJ. Advancements in global phosphoproteomics profiling: overcoming challenges in sensitivity and quantification. Proteomics. (2025) 25:e202400087. doi:&#xa0; 10.1002/pmic.202400087, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.202400087</ArticleId><ArticleId IdType="pmc">PMC11735659</ArticleId><ArticleId IdType="pubmed">39696887</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido-Rodriguez M, Potel C, Burtscher ML, Becher I, Rodriguez-Mier P, M&#xfc;ller-Dott S, et al. Evaluating signaling pathway inference from kinase-substrate interactions and phosphoproteomics data. bioRxiv. (2024) .10:21. doi:&#xa0; 10.1101/2024.10.21.619348</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.10.21.619348</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Min HM, Cai ShaoLi CS, Su JingQian SJ. The pathogenesis of sepsis and potential therapeutic targets. Int J Mol Sci. (2019) 20:5376. doi:&#xa0; 10.3390/ijms20215376, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20215376</ArticleId><ArticleId IdType="pmc">PMC6862039</ArticleId><ArticleId IdType="pubmed">31671729</ArticleId></ArticleIdList></Reference><Reference><Citation>Bode C, Weis S, Sauer A, Wendel-Garcia P, David S. Targeting the host response in sepsis: current approaches and future evidence. Crit Care. (2023) 27:478. doi:&#xa0; 10.1186/s13054-023-04762-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04762-6</ArticleId><ArticleId IdType="pmc">PMC10698949</ArticleId><ArticleId IdType="pubmed">38057824</ArticleId></ArticleIdList></Reference><Reference><Citation>Daix T, Mathonnet A, Brakenridge S, Dequin P-F, Mira J-P, Berbille F, et al. Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann Intensive Care. (2023) 13:17. doi:&#xa0; 10.1186/s13613-023-01109-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-023-01109-w</ArticleId><ArticleId IdType="pmc">PMC10008152</ArticleId><ArticleId IdType="pubmed">36906875</ArticleId></ArticleIdList></Reference><Reference><Citation>Rienzo M, Skirecki T, Monneret G, Timsit J-F. Immune checkpoint inhibitors for the treatment of sepsis: insights from preclinical and clinical development. Expert Opin Investig Drugs. (2022) 31:885&#x2013;94. doi:&#xa0; 10.1080/13543784.2022.2102477, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2022.2102477</ArticleId><ArticleId IdType="pubmed">35944174</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe E, Nishida O, Kakihana Y, Odani M, Okamura T, Harada T, et al. Pharmacokinetics, pharmacodynamics, and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1/2 study. Shock. (2020) 53:686&#x2013;94. doi:&#xa0; 10.1097/.0000000000001443, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/.0000000000001443</ArticleId><ArticleId IdType="pmc">PMC7448837</ArticleId><ArticleId IdType="pubmed">31513050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SI, Kim NY, Chung C, Park D, Kang DH, Kim DK, et al. IL-6 and PD-1 antibody blockade combination therapy regulate inflammation and T lymphocyte apoptosis in murine model of sepsis. BMC Immunol. (2025) 26:3. doi:&#xa0; 10.1186/s12865-024-00679-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-024-00679-z</ArticleId><ArticleId IdType="pmc">PMC11731149</ArticleId><ArticleId IdType="pubmed">39806304</ArticleId></ArticleIdList></Reference><Reference><Citation>Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. (2023) 19:460&#x2013;76. doi:&#xa0; 10.1038/s41574-023-00833-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-023-00833-4</ArticleId><ArticleId IdType="pmc">PMC10153049</ArticleId><ArticleId IdType="pubmed">37130947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Jiao Y, Li C, Liang X, Jia H, Nie Z, et al. Dimethyl itaconate alleviates the inflammatory responses of macrophages in sepsis. Inflammation. (2021) 44:549&#x2013;57. doi:&#xa0; 10.1007/s10753-020-01352-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-020-01352-4</ArticleId><ArticleId IdType="pubmed">33029757</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Guan B, Chen K, Feng Z, Guo K, Wang X, et al. Fucoxanthin attenuates inflammation via interferon regulatory factor 3 (IRF3) to improve sepsis. J Agric Food Chem. (2023) 71:12497&#x2013;510. doi:&#xa0; 10.1021/acs.jafc.3c03247, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.3c03247</ArticleId><ArticleId IdType="pubmed">37560933</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Xiao J, Chen S, Zhao H, Zhang X, Feng Z, et al. Aloin ameliorates cecal&#xa0;ligation and puncture-induced sepsis in mice by attenuating inflammation and modulating gut microbiota. Food Sci Hum Wellness. (2025) 14:9250034. doi:&#xa0; 10.26599/.2024.9250034</Citation><ArticleIdList><ArticleId IdType="doi">10.26599/.2024.9250034</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Xiao J, Deng X, Lin X, Xie L, Ye H, et al. Combining Aloin with TIENAM ameliorates cecal ligation and puncture-induced sepsis in mice by attenuating inflammation and modulating abdominal cavity microbiota. Int Immunopharmacol. (2024) 141:112925. doi:&#xa0; 10.1016/j.intimp.2024.112925, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2024.112925</ArticleId><ArticleId IdType="pubmed">39154534</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41656807</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1672-7347</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences</Title><ISOAbbreviation>Zhong Nan Da Xue Xue Bao Yi Xue Ban</ISOAbbreviation></Journal><ArticleTitle>Mechanisms of gypenosides in type 2 diabetes mellitus via regulation of m6A methylase METTL3/14 and demethylase FTO.</ArticleTitle><Pagination><StartPage>1735</StartPage><EndPage>1754</EndPage><MedlinePgn>1735-1754</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11817/j.issn.1672-7347.2025.250091</ELocationID><ELocationID EIdType="pii" ValidYN="Y">1672-7347(2025)10-1735-20</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Type 2 diabetes mellitus (T2DM) is characterized by insufficient insulin secretion and insulin resistance. Gypenosides (GPs) are the major bioactive saponins extracted from Gynostemma pentaphyllum. Previous studies suggest that GPs have beneficial effects on T2DM, but the underlying mechanisms remain unclear. This study aims to investigate whether GPs exert therapeutic effects by influencing RNA N<sup>6</sup>-methyladenosine (m6A) methylation modification, thereby regulating the downstream phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Expression levels and methylation changes of <i>METTL3, METTL14</i>, and <i>FTO</i> in T2DM were analyzed using public databases, and related pathways were explored via gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The main active components of GPs were screened from pharmacological databases, followed by compound-target network construction, enrichment analyses, and prediction of potential targets and pathways. A T2DM model was induced in Sprague-Dawley rats using a high-fat/high-sugar diet combined with low-dose streptozotocin. Rats were randomly divided into 4 groups: GPs-treated group (GPG, 400 mg/kg), positive control group (PCG, metformin 100 mg/kg), normal saline control group (CONTROL), and T2DM model group (MODEL). Fasting blood glucose (FBG), oral glucose tolerance test (OGTT)-area under the glucose curve from 0 to 120 min (<i>AUC<sub>0-120</sub></i>), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), serum inflammatory factors, and tissue pathology of pancreas and liver hematoxylin and eosin (HE) staining were assessed. Real-time fluorescence quantitative PCR and Western blotting were used to detect RNA and protein expression levels of <i>METTL3, METTL14, FTO</i>, <i>PI3K</i>, and <i>AKT</i> in pancreatic tissues. Molecular docking was applied to evaluate interactions between GPs' main components and <i>METTL3</i>, <i>METTL14</i>, and <i>FTO</i> to infer potential binding modes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bioinformatic analyses showed downregulation of <i>METTL3</i>/<i>14</i> and upregulation of FTO in T2DM samples (all <i>P</i>&lt;0.05), with enrichment in pathways related to insulin signaling, PI3K/AKT activation, oxidative stress response, and hormone secretion. Network pharmacology indicated that GPs components may act on targets involved in RNA modification and insulin-related pathways. In diabetic rats, GPs significantly reduced FBG, improved glucose tolerance, decreased HOMA-IR, and decreased the serum tumor necrosis factor-&#x3b1; (TNF-&#x3b1;) and interleukin (IL)-6 levels compared with MODEL (all <i>P</i>&lt;0.05). Pancreatic pathology showed alleviated islet injury and improved cell morphology. GPs treatment up-regulated <i>METTL3/14</i> mRNA and protein levels, and down-regulated <i>FTO</i> mRNA/protein levels in pancreatic tissue (all <i>P</i>&lt;0.05). PI3K and AKT expression levels increased (both <i>P</i>&lt;0.05), consistent with activation of downstream signals related to glucose uptake and improved insulin sensitivity. Metformin also improved metabolic indices but exhibited a different regulatory pattern on m6A-related enzymes compared with GPs. Molecular docking revealed stable interactions between core GPs saponin structures and methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), or obesity-associated protein (FTO), suggesting that GPs may directly or indirectly modulate m6A regulatory proteins.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GPs can effectively improve glucose-metabolism disorders, reduce inflammation, and protect pancreatic tissue in T2DM rats. The mechanisms may be associated with <i>METTL3/14</i> up-regulation and <i>FTO</i> down-regulation, leading to enhanced m6A methylation and subsequent activation of the PI3K/AKT signaling pathway. These findings provide strong evidence for GPs regulation of epigenetic m6A RNA modification and insulin-related downstream pathways, and suggest that natural compounds targeting m6A regulation may be explored in the future for metabolic disease interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Chemistry and Biochemistry, Guizhou Medical University, Guiyang 550004, China. 1842443937@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shaoqian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Chemistry and Biochemistry, Guizhou Medical University, Guiyang 550004, China. 2246454794@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Renwei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Chemistry and Biochemistry, Guizhou Medical University, Guiyang 550004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Hebei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Chemistry and Biochemistry, Guizhou Medical University, Guiyang 550004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yating</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Chemistry and Biochemistry, Guizhou Medical University, Guiyang 550004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Mingyi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Chemistry and Biochemistry, Guizhou Medical University, Guiyang 550004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Guangbin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Chemistry and Biochemistry, Guizhou Medical University, Guiyang 550004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jianfei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Chemistry and Biochemistry, Guizhou Medical University, Guiyang 550004, China. tyczyc@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory of Chemistry and Biochemistry, Guizhou Medical University, Guiyang 550004, China. wuning@gmc.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S202210660105 and S202310660055</GrantID><Agency>College Students' Innovative Entrepreneurial Training Plan Program of Guizhou Province, China</Agency><Country/></Grant><Grant><GrantID>CC BY-NC-ND 4.0 and //creativecommons.org/licenses/by-nc-nd/4.0/</GrantID><Agency>This is an open access article under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhong Nan Da Xue Xue Bao Yi Xue Ban</MedlineTA><NlmUniqueID>101230586</NlmUniqueID><ISSNLinking>1672-7347</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="D000071516">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.-</RegistryNumber><NameOfSubstance UI="D008780">Methyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C474918">gypenoside</NameOfSubstance></Chemical><Chemical><RegistryNumber>CLE6G00625</RegistryNumber><NameOfSubstance UI="C010223">N-methyladenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="C526492">FTO protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.62</RegistryNumber><NameOfSubstance UI="C468275">METTL3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071516" MajorTopicYN="Y">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008780" MajorTopicYN="Y">Methyltransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029774" MajorTopicYN="N">Gynostemma</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="N">Insulin Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N" AutoHM="Y">Plant Extracts</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>&#x76ee;&#x7684;</b>: 2&#x578b;&#x7cd6;&#x5c3f;&#x75c5;(type 2 diabetes mellitus&#xff0c;T2DM)&#x4ee5;&#x80f0;&#x5c9b;&#x7d20;&#x5206;&#x6ccc;&#x4e0d;&#x8db3;&#x53ca;&#x80f0;&#x5c9b;&#x7d20;&#x62b5;&#x6297;&#x4e3a;&#x7279;&#x5f81;&#x3002;&#x7ede;&#x80a1;&#x84dd;&#x7682;&#x82f7;(gypenosides&#xff0c;GPs)&#x662f;&#x4ece;&#x7ede;&#x80a1;&#x84dd;&#x4e2d;&#x63d0;&#x53d6;&#x7684;&#x4e3b;&#x8981;&#x6d3b;&#x6027;&#x7682;&#x82f7;&#xff0c;&#x524d;&#x671f;&#x7814;&#x7a76;&#x63d0;&#x793a;&#x5176;&#x5bf9;T2DM&#x5177;&#x6709;&#x6539;&#x5584;&#x4f5c;&#x7528;&#xff0c;&#x4f46;&#x5176;&#x6cbb;&#x7597;&#x673a;&#x5236;&#x5c1a;&#x672a;&#x9610;&#x660e;&#x3002;&#x672c;&#x7814;&#x7a76;&#x65e8;&#x5728;&#x63a2;&#x8ba8;GPs&#x662f;&#x5426;&#x901a;&#x8fc7;&#x5f71;&#x54cd;RNA&#x7684;m6A&#x7532;&#x57fa;&#x5316;&#x4fee;&#x9970;&#xff0c;&#x8fdb;&#x800c;&#x8c03;&#x63a7;&#x4e0b;&#x6e38;&#x78f7;&#x8102;&#x9170;&#x808c;&#x9187;3&#x6fc0;&#x9176;(phosphoinositide 3-kinase&#xff0c;PI3K)/&#x86cb;&#x767d;&#x6fc0;&#x9176;B(protein kinase B&#xff0c;AKT)&#x4fe1;&#x53f7;&#x901a;&#x8def;&#xff0c;&#x4ece;&#x800c;&#x53d1;&#x6325;&#x6cbb;&#x7597;&#x4f5c;&#x7528;&#x3002;<b>&#x65b9;&#x6cd5;</b>: &#x901a;&#x8fc7;&#x5206;&#x6790;&#x516c;&#x5171;&#x6570;&#x636e;&#x5e93;&#x4e2d;T2DM&#x60a3;&#x8005;&#x4e2d;<i>METTL3</i>&#x3001;<i>METTL14</i>&#x53ca;<i>FTO</i>&#x7684;&#x8868;&#x8fbe;&#x6c34;&#x5e73;&#x53ca;&#x7532;&#x57fa;&#x5316;&#x53d8;&#x5316;&#xff0c;&#x5e76;&#x5229;&#x7528;&#x57fa;&#x56e0;&#x672c;&#x4f53;&#x8bba;(gene ontology&#xff0c;GO)&#x548c;&#x4eac;&#x90fd;&#x57fa;&#x56e0;&#x548c;&#x57fa;&#x56e0;&#x7ec4;&#x6570;&#x636e;&#x5e93;(Kyoto Encyclopedia of Genes and Genomes&#xff0c;KEGG)&#x5bcc;&#x96c6;&#x5206;&#x6790;&#x63a2;&#x7d22;&#x76f8;&#x5173;&#x901a;&#x8def;&#x3002;&#x4ece;&#x5df2;&#x5efa;&#x7acb;&#x7684;&#x836f;&#x7406;&#x5b66;&#x6570;&#x636e;&#x5e93;&#x4e2d;&#x7b5b;&#x9009;GPs&#x7684;&#x4e3b;&#x8981;&#x6d3b;&#x6027;&#x6210;&#x5206;&#xff0c;&#x6784;&#x5efa;&#x5316;&#x5408;&#x7269;-&#x9776;&#x70b9;&#x7f51;&#x7edc;&#x5e76;&#x8fdb;&#x884c;&#x5bcc;&#x96c6;&#x5206;&#x6790;&#xff0c;&#x9884;&#x6d4b;&#x5176;&#x6f5c;&#x5728;&#x4f5c;&#x7528;&#x9776;&#x70b9;&#x4e0e;&#x901a;&#x8def;&#x3002;&#x91c7;&#x7528;&#x9ad8;&#x8102;&#x9ad8;&#x7cd6;&#x996e;&#x98df;&#x8054;&#x5408;&#x4f4e;&#x5242;&#x91cf;&#x94fe;&#x8132;&#x4f50;&#x83cc;&#x7d20;&#x8bf1;&#x5bfc;Sprague-Dawley&#x5927;&#x9f20;T2DM&#x6a21;&#x578b;&#x3002;&#x5c06;&#x5927;&#x9f20;&#x968f;&#x673a;&#x5206;&#x4e3a;4&#x7ec4;:GPs&#x6cbb;&#x7597;&#x7ec4;(GPs-treated group&#xff0c;GPG&#xff0c;GPs 400 mg/kg)&#x3001;&#x9633;&#x6027;&#x5bf9;&#x7167;&#x7ec4;(positive control group&#xff0c;PCG&#xff0c;&#x4e8c;&#x7532;&#x53cc;&#x80cd;100 mg/kg)&#x3001;&#x751f;&#x7406;&#x76d0;&#x6c34;&#x5bf9;&#x7167;&#x7ec4;(normal saline control group&#xff0c;CONTROL)&#x548c;T2DM&#x6a21;&#x578b;&#x7ec4;(T2DM model group&#xff0c;MODEL)&#x3002;&#x8bc4;&#x4f30;&#x7a7a;&#x8179;&#x8840;&#x7cd6;(fasting blood glucose&#xff0c;FBG)&#x3001;&#x53e3;&#x670d;&#x8461;&#x8404;&#x7cd6;&#x8010;&#x91cf;&#x8bd5;&#x9a8c;(oral glucose tolerance test &#xff0c;OGTT)&#x53ca;0~120 min&#x8840;&#x7cd6;&#x66f2;&#x7ebf;&#x4e0b;&#x9762;&#x79ef;(area under the glucose curve from 0 to 120 min&#xff0c;<i>AUC</i><sub>0&#x2013;120</sub>)&#x3001;&#x7a7a;&#x8179;&#x80f0;&#x5c9b;&#x7d20;(fasting insulin&#xff0c;FINS)&#x3001;&#x80f0;&#x5c9b;&#x7d20;&#x62b5;&#x6297;&#x7a33;&#x6001;&#x6a21;&#x578b;&#x8bc4;&#x4f30;(homeostasis model assessment of insulin resistance&#xff0c;HOMA-IR)&#x53ca;&#x8840;&#x6e05;&#x708e;&#x75c7;&#x56e0;&#x5b50;&#x6c34;&#x5e73;&#x3002;&#x91c7;&#x7528;&#x82cf;&#x6728;&#x7cbe;-&#x4f0a;&#x7ea2;(hematoxylin and eosin&#xff0c;HE)&#x67d3;&#x8272;&#x5bf9;&#x80f0;&#x817a;&#x548c;&#x809d;&#x7ec4;&#x7ec7;&#x8fdb;&#x884c;&#x7ec4;&#x7ec7;&#x75c5;&#x7406;&#x5b66;&#x68c0;&#x67e5;&#x3002;&#x5229;&#x7528;&#x5b9e;&#x65f6;&#x8367;&#x5149;&#x5b9a;&#x91cf;PCR&#x548c;&#x86cb;&#x767d;&#x8d28;&#x5370;&#x8ff9;&#x6cd5;&#x68c0;&#x6d4b;&#x80f0;&#x817a;&#x7ec4;&#x7ec7;&#x4e2d;<i>METTL3</i>&#x3001;<i>METTL14</i>&#x3001;<i>FTO</i>&#x3001;<i>PI3K</i>&#x548c;<i>AKT</i>&#x7684;RNA&#x53ca;&#x86cb;&#x767d;&#x8d28;&#x8868;&#x8fbe;&#x6c34;&#x5e73;&#x3002;&#x6b64;&#x5916;&#xff0c;&#x901a;&#x8fc7;&#x5206;&#x5b50;&#x5bf9;&#x63a5;&#x8bc4;&#x4f30;GPs&#x4e3b;&#x8981;&#x6210;&#x5206;&#x4e0e;&#x7532;&#x57fa;&#x8f6c;&#x79fb;&#x9176;&#x6837;&#x86cb;&#x767d;3(methyltransferase-like 3&#xff0c;METTL3)&#x3001;&#x7532;&#x57fa;&#x8f6c;&#x79fb;&#x9176;&#x6837;&#x86cb;&#x767d;14(methyltransferase-like 14&#xff0c;METTL14)&#x548c;&#x80a5;&#x80d6;&#x76f8;&#x5173;&#x86cb;&#x767d;(obesity-associated protein&#xff0c;FTO)&#x4e4b;&#x95f4;&#x7684;&#x76f8;&#x4e92;&#x4f5c;&#x7528;&#xff0c;&#x4ee5;&#x786e;&#x5b9a;&#x6f5c;&#x5728;&#x7ed3;&#x5408;&#x6a21;&#x5f0f;&#x3002;<b>&#x7ed3;&#x679c;</b>: &#x751f;&#x7269;&#x4fe1;&#x606f;&#x5b66;&#x5206;&#x6790;&#x663e;&#x793a;&#xff0c;T2DM&#x6837;&#x672c;&#x4e2d;<i>METTL3</i>&#x4e0e;<i>METTL14</i>&#x8868;&#x8fbe;&#x4e0b;&#x8c03;&#xff0c;&#x800c;<i>FTO</i>&#x8868;&#x8fbe;&#x4e0a;&#x8c03;(&#x5747;<i>P</i>&lt;0.05)&#xff0c;&#x5e76;&#x4f34;&#x6709;&#x80f0;&#x5c9b;&#x7d20;&#x4fe1;&#x53f7;&#x3001;PI3K/AKT&#x6fc0;&#x6d3b;&#x3001;&#x6c27;&#x5316;&#x5e94;&#x6fc0;&#x53cd;&#x5e94;&#x548c;&#x6fc0;&#x7d20;&#x5206;&#x6ccc;&#x76f8;&#x5173;&#x901a;&#x8def;&#x7684;&#x5bcc;&#x96c6;&#x3002;&#x7f51;&#x7edc;&#x836f;&#x7406;&#x5b66;&#x63d0;&#x793a;GPs&#x6210;&#x5206;&#x53ef;&#x80fd;&#x4f5c;&#x7528;&#x4e8e;RNA&#x4fee;&#x9970;&#x548c;&#x80f0;&#x5c9b;&#x7d20;&#x76f8;&#x5173;&#x901a;&#x8def;&#x9776;&#x70b9;&#x3002;&#x5728;T2DM&#x5927;&#x9f20;&#x4e2d;&#xff0c;&#x4e0e;MODEL&#x76f8;&#x6bd4;&#xff0c;GPs&#x6cbb;&#x7597;&#x663e;&#x8457;&#x964d;&#x4f4e;&#x4e86;FBG&#xff0c;&#x6539;&#x5584;&#x4e86;&#x8461;&#x8404;&#x7cd6;&#x8010;&#x91cf;&#xff0c;&#x964d;&#x4f4e;&#x4e86;HOMA-IR&#x503c;&#xff0c;&#x4e5f;&#x964d;&#x4f4e;&#x4e86;&#x8840;&#x6e05;&#x80bf;&#x7624;&#x574f;&#x6b7b;&#x56e0;&#x5b50;-&#x3b1;(tumor necrosis factor-&#x3b1;&#xff0c;TNF-&#x3b1;)&#x548c;&#x767d;&#x7ec6;&#x80de;&#x4ecb;&#x7d20;(interleukin&#xff0c;IL)-6&#x6c34;&#x5e73;(&#x5747;<i>P</i>&lt;0.05)&#xff0c;&#x540c;&#x65f6;&#x80f0;&#x817a;&#x7ec4;&#x7ec7;&#x75c5;&#x7406;&#x5b66;&#x68c0;&#x67e5;&#x663e;&#x793a;&#x80f0;&#x5c9b;&#x635f;&#x4f24;&#x51cf;&#x8f7b;&#x3001;&#x7ec6;&#x80de;&#x5f62;&#x6001;&#x6539;&#x5584;&#x3002;GPs&#x6cbb;&#x7597;&#x4f7f;&#x80f0;&#x817a;&#x7ec4;&#x7ec7;&#x4e2d;<i>METTL3</i>&#x548c;<i>METTL14</i>&#x7684;mRNA&#x548c;&#x86cb;&#x767d;&#x8d28;&#x8868;&#x8fbe;&#x6c34;&#x5e73;&#x4e0a;&#x8c03;&#xff0c;&#x800c;<i>FTO</i>&#x7684;mRNA&#x548c;&#x86cb;&#x767d;&#x8d28;&#x8868;&#x8fbe;&#x6c34;&#x5e73;&#x4e0b;&#x8c03;(&#x5747;<i>P</i>&lt;0.05)&#x3002;&#x540c;&#x65f6;&#xff0c;PI3K&#x548c;AKT&#x8868;&#x8fbe;&#x6c34;&#x5e73;&#x5747;&#x5347;&#x9ad8;(&#x5747;<i>P</i>&lt;0.05)&#xff0c;&#x4e0e;&#x8461;&#x8404;&#x7cd6;&#x6444;&#x53d6;&#x548c;&#x80f0;&#x5c9b;&#x7d20;&#x654f;&#x611f;&#x6027;&#x76f8;&#x5173;&#x7684;&#x4e0b;&#x6e38;&#x4fe1;&#x53f7;&#x901a;&#x8def;&#x6fc0;&#x6d3b;&#x4e00;&#x81f4;&#x3002;&#x4e8c;&#x7532;&#x53cc;&#x80cd;&#x4ea6;&#x53ef;&#x6539;&#x5584;&#x4ee3;&#x8c22;&#x6307;&#x6807;&#xff0c;&#x4f46;&#x5176;&#x5bf9;m6A&#x76f8;&#x5173;&#x9176;&#x7684;&#x8c03;&#x63a7;&#x6a21;&#x5f0f;&#x4e0e;GPs&#x4e0d;&#x540c;&#x3002;&#x5206;&#x5b50;&#x5bf9;&#x63a5;&#x7ed3;&#x679c;&#x663e;&#x793a;GPs&#x7684;&#x4e3b;&#x8981;&#x7682;&#x82f7;&#x7ed3;&#x6784;&#x4e0e;METTL3&#x3001;METTL14&#x6216;FTO&#x4e4b;&#x95f4;&#x5177;&#x6709;&#x7a33;&#x5b9a;&#x76f8;&#x4e92;&#x4f5c;&#x7528;&#xff0c;&#x63d0;&#x793a;GPs&#x5bf9;m6A&#x76f8;&#x5173;&#x8c03;&#x63a7;&#x86cb;&#x767d;&#x5177;&#x6709;&#x76f4;&#x63a5;&#x6216;&#x95f4;&#x63a5;&#x8c03;&#x8282;&#x4f5c;&#x7528;&#x3002;<b>&#x7ed3;&#x8bba;</b>: GPs&#x80fd;&#x591f;&#x6709;&#x6548;&#x6539;&#x5584;T2DM&#x5927;&#x9f20;&#x7684;&#x7cd6;&#x4ee3;&#x8c22;&#x7d0a;&#x4e71;&#x3001;&#x51cf;&#x8f7b;&#x708e;&#x75c7;&#x53cd;&#x5e94;&#x5e76;&#x4fdd;&#x62a4;&#x80f0;&#x817a;&#x7ec4;&#x7ec7;&#xff0c;&#x5176;&#x4f5c;&#x7528;&#x673a;&#x5236;&#x53ef;&#x80fd;&#x4e0e;METTL3/METTL14&#x4e0a;&#x8c03;&#xff0c;FTO&#x4e0b;&#x8c03;&#x800c;&#x589e;&#x5f3a;m6A&#x7532;&#x57fa;&#x5316;&#x6709;&#x5173;&#xff0c;&#x589e;&#x5f3a;m6A&#x4fee;&#x9970;&#x8fdb;&#x800c;&#x6fc0;&#x6d3b;PI3K/AKT&#x4fe1;&#x53f7;&#x901a;&#x8def;&#x3002;&#x8fd9;&#x4e3a;GPs&#x8c03;&#x63a7;&#x8868;&#x89c2;&#x9057;&#x4f20;RNA&#x4fee;&#x9970;&#x53ca;&#x4e0b;&#x6e38;&#x80f0;&#x5c9b;&#x7d20;&#x76f8;&#x5173;&#x901a;&#x8def;&#x63d0;&#x4f9b;&#x4e86;&#x6709;&#x529b;&#x8bc1;&#x636e;&#xff0c;&#x4e5f;&#x63d0;&#x793a;&#x672a;&#x6765;&#x53ef;&#x63a2;&#x7d22;&#x4ee5;m6A&#x4e3a;&#x9776;&#x70b9;&#x7684;&#x5929;&#x7136;&#x5316;&#x5408;&#x7269;&#x7528;&#x4e8e;&#x4ee3;&#x8c22;&#x6027;&#x75be;&#x75c5;&#x7684;&#x5e72;&#x9884;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">METTL14</Keyword><Keyword MajorTopicYN="N">METTL3</Keyword><Keyword MajorTopicYN="N">PI3K/AKT signaling pathway</Keyword><Keyword MajorTopicYN="N">RNA modification</Keyword><Keyword MajorTopicYN="N">gypenosides</Keyword><Keyword MajorTopicYN="N">m6A methylation modification</Keyword><Keyword MajorTopicYN="N">obesity-associated protein</Keyword><Keyword MajorTopicYN="N">type 2 diabetes mellitus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>9</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41656807</ArticleId><ArticleId IdType="doi">10.11817/j.issn.1672-7347.2025.250091</ArticleId><ArticleId IdType="pii">1672-7347(2025)10-1735-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang B, Li M, Gao H, et al. Chemical composition of tetraploid <i>Gynostemma pentaphyllum</i> gypenosides and their suppression on inflammatory response by NF-&#x3ba;B/MAPKs/AP-1 signaling pathways[J]. Food Sci Nutr, 2020, 8(2):1197-1207. https://doi.org/10.1002/fsn3.1407.</Citation></Reference><Reference><Citation>Lee YZ, Kow ASF, Lee QL, et al. Antidiabetic potentials of gypenosides:a review on the preclinical effects in glucose and insulin modulation as well as diabetes-related complications[J]. Naunyn Schmiedebergs Arch Pharmacol, 2025, 398(11):14813-14829. https://doi.org/10.1007/s00210-025-04265-x.</Citation></Reference><Reference><Citation>Su C, Li N, Ren R, et al. Progress in the medicinal value, bioactive compounds, and pharmacological activities of <i>Gynostemma pentaphyllum</i>[J]. Molecules, 2021, 26(20):6249. https://doi.org/10.3390/molecules26206249.</Citation></Reference><Reference><Citation>Jiang Y, Cheng X, Zhao M, et al. Gypenoside-14 reduces depression via downregulation of the nuclear factor kappa B(NF-kB)signaling pathway on the lipopolysaccharide(LPS)-induced depression model[J]. Pharmaceuticals, 2023, 16(8):1152. https://doi.org/10.3390/ph16081152.</Citation></Reference><Reference><Citation>Liu J, Luo G, Sun J, et al. METTL14 is essential for &#x3b2;-cell survival and insulin secretion[J]. Biochim Biophys Acta BBA Mol Basis Dis, 2019, 1865(9):2138-2148. https://doi.org/10. 1016/j.bbadis.2019.04.011.</Citation></Reference><Reference><Citation>Chu X, Wang X, Feng KQ, et al. Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-&#x3ba;B-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model[J]. Lipids Health Dis, 2025, 24(1):55. https://doi.org/10.1186/s12944-025-02483-z.</Citation></Reference><Reference><Citation>Nemati M, Ebrahimi Z, Karbalaei N, et al. <i>In vitro</i> and <i>in vivo</i> improvement of islet quality and transplantation successes following islet treatment with biomaterials in diabetic rats[J]. J Diabetes Res, 2023, 2023:1399917. https://doi. org/10.1155/2023/1399917.</Citation></Reference><Reference><Citation>Wu W, Wang S, Liu Q, et al. Metformin protects against LPS-induced intestinal barrier dysfunction by activating AMPK pathway[J]. Mol Pharmaceutics, 2018, 15(8):3272-3284. https://doi.org/10.1021/acs.molpharmaceut.8b00332.</Citation></Reference><Reference><Citation>He Q, Li JK, Li F, et al. Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats[J]. World J Gastroenterol, 2015, 21(7):2058-2066. https://doi.org/10.3748/wjg.v21.i7.2058.</Citation></Reference><Reference><Citation>Keller MP, Choi Y, Wang P, et al. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility[J]. Genome Res, 2008, 18(5):706-716. https://doi.org/10.1101/gr.074914.107.</Citation></Reference><Reference><Citation>Sch&#xf6;ller E, Weichmann F, Treiber T, et al. Interactions, localization, and phosphorylation of the m6A generating METTL3-METTL14-WTAP complex[J]. RNA, 2018, 24(4):499-512. https://doi.org/10.1261/rna.064063.117.</Citation></Reference><Reference><Citation>Wang Z, Wang Z, Huang W, et al. Antioxidant and anti-inflammatory activities of an anti-diabetic polysaccharide extracted from <i>Gynostemma pentaphyllum</i> herb[J]. Int J Biol Macromol, 2020, 145:484-491. https://doi.org/10.1016/j.ijbiomac. 2019.12.213.</Citation></Reference><Reference><Citation>Xu K, Lu G, Feng Q, et al. Hepatoprotective effect of protocatechuic acid against type 2 diabetes-induced liver injury[J]. Pharm Biol, 2023, 61(1):737-745. https://doi.org/10.1080/13880209.2023.2181359.</Citation></Reference><Reference><Citation>Zhang H, Chen X, Zong B, et al. Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation[J]. J Cell Mol Med, 2018, 22(9):4437-4448. https://doi.org/10.1111/jcmm.13743.</Citation></Reference><Reference><Citation>Cao JJ, Zheng RD, Chang XY, et al. <i>Cyclocarya paliurus</i> triterpenoids suppress hepatic gluconeogenesis via AMPK-mediated cAMP/PKA/CREB pathway[J]. Phytomedicine, 2022, 102:154175. https://doi.org/10.1016/j.phymed.2022.154175.</Citation></Reference><Reference><Citation>Dubin DT, Taylor RH. The methylation state of poly A-containing messenger RNA from cultured <i>Hamster</i> cells[J]. Nucleic Acids Res, 1975, 2(10):1653-1668. https://doi.org/10. 1093/nar/2.10.1653.</Citation></Reference><Reference><Citation>Li K, Ma C, Li H, et al. Medicinal value and potential therapeutic mechanisms of <i>Gynostemma pentaphyllum</i>(thunb.)makino and its derivatives:an overview[J]. Curr Top Med Chem, 2019, 19(31):2855-2867. https://doi.org/10. 2174/1568026619666191114104718.</Citation></Reference><Reference><Citation>Xie JB, Xie P, Guo M, et al. Protective effect of heat-processed <i>Gynostemma pentaphyllum</i> on high fat diet-induced glucose metabolic disorders mice[J]. Front Pharmacol, 2023, 14:1215150. https://doi.org/10.3389/fphar.2023.1215150.</Citation></Reference><Reference><Citation>He C, Wang K, Xia J, et al. Natural exosomes-like nanoparticles in mung bean sprouts possesses anti-diabetic effects via activation of PI3K/Akt/GLUT4/GSK-3&#x3b2; signaling pathway[J]. J Nanobiotechnology, 2023, 21(1):349. https://doi.org/10.1186/s12951-023-02120-w.</Citation></Reference><Reference><Citation>Huyen VT, Phan DV, Thang P, et al. <i>Gynostemma pentaphyllum</i> tea improves insulin sensitivity in type 2 diabetic patients[J]. J Nutr Metab, 2013, 2013:765383. https://doi.org/10. 1155/2013/765383.</Citation></Reference><Reference><Citation>Stagi S, Ricci F, Bianconi M, et al. Retrospective evaluation of metformin and/or metformin plus a new polysaccharide complex in treating severe hyperinsulinism and insulin resistance in obese children and adolescents with metabolic syndrome[J]. Nutrients, 2017, 9(5):524. https://doi.org/10. 3390/nu9050524.</Citation></Reference><Reference><Citation>Weng X, Lou YY, Wang YS, et al. New dammarane-type glycosides from <i>Gynostemma pentaphyllum</i> and their lipid-lowering activity[J]. Bioorg Chem, 2021, 111:104843. https://doi. org/10.1016/j.bioorg.2021.104843.</Citation></Reference><Reference><Citation>Zhang HJ, Ji BP, Chen G, et al. A combination of grape seed-derived procyanidins and gypenosides alleviates insulin resistance in mice and HepG2 cells[J]. J Food Sci, 2009, 74(1):H1-H7. https://doi.org/10.1111/j.1750-3841.2008.00976.x.</Citation></Reference><Reference><Citation>De Jesus DF, Zhang Z, Kahraman S, et al. M(6)a mRNA methylation regulates human &#x3b2;-cell biology in physiological states and in type 2 diabetes[J]. Nat Metab, 2019, 1(8):765-774. https://doi.org/10.1038/s42255-019-0089-9.</Citation></Reference><Reference><Citation>Pang Y, Zhu H, Xu J, et al. &#x3b2;-arrestin-2 is involved in irisin induced glucose metabolism in type 2 diabetes via p38 MAPK signaling[J]. Exp Cell Res, 2017, 360(2):199-204. https://doi.org/10.1016/j.yexcr.2017.09.006.</Citation></Reference><Reference><Citation>Sun H, Liu X, Long SR, et al. Antidiabetic effects of pterostilbene through PI3K/Akt signal pathway in high fat diet and STZ-induced diabetic rats[J]. Eur J Pharmacol, 2019, 859:172526. https://doi.org/10.1016/j.ejphar.2019.172526.</Citation></Reference><Reference><Citation>Xu Z, Jia K, Wang H, et al. METTL14-regulated PI3K/Akt signaling pathway via PTEN affects HDAC5-mediated epithelial-mesenchymal transition of renal tubular cells in diabetic kidney disease[J]. Cell Death Dis, 2021, 12(1):32. https://doi.org/10.1038/s41419-020-03312-0.</Citation></Reference><Reference><Citation>Li M, Deng L, Xu G. METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of &#x3b1;-Klotho[J]. Mol Med, 2021, 27(1):106. https://doi. org/10.1186/s10020-021-00365-5.</Citation></Reference><Reference><Citation>Liu X, He H, Zhang F, et al. m6A methylated EphA2 and VEGFA through IGF<sub>2</sub>BP<sub>2</sub>/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling[J]. Cell Death Dis, 2022, 13(5):483. https://doi.org/10. 1038/s41419-022-04950-2.</Citation></Reference><Reference><Citation>Shen CY, Jiang JG, Shi MM, et al. Comparison of the effects and inhibitory pathways of the constituents from <i>Gynostemma pentaphyllum</i> against LPS-induced inflammatory response[J]. J Agric Food Chem, 2018, 66(43):11337-11346. https://doi.org/10. 1021/acs.jafc.8b03903.</Citation></Reference><Reference><Citation>Wang Y, Sun J, Lin Z, et al. M(6)a mRNA methylation controls functional maturation in neonatal murine &#x3b2;-cells[J]. Diabetes, 2020, 69(8):1708-1722. https://doi.org/10.2337/db19-0906.</Citation></Reference><Reference><Citation>Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation:examining the links[J]. Int J Physiol Pathophysiol Pharmacol, 2019, 11(3):45-63.</Citation></Reference><Reference><Citation>Aierken A, Li BL, Liu P, et al. Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling pathway[J]. Stem Cell Res Ther, 2022, 13(1):164. https://doi.org/10.1186/s13287-022-02832-0.</Citation></Reference><Reference><Citation>S&#xe1;nchez-Ort&#xed; JV, Correa-Ghisays P, Balanz&#xe1;-Mart&#xed;nez V, et al. Inflammation and lipid metabolism as potential biomarkers of memory impairment across type 2 diabetes mellitus and severe mental disorders[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2023, 127:110817. https://doi.org/10.1016/j.pnpbp. 2023.110817.</Citation></Reference><Reference><Citation>Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes:a global perspective[J]. Endocrinol Metab Clin North Am, 2021, 50(3):337-355. https://doi.org/10.1016/j.ecl. 2021.05.013.</Citation></Reference><Reference><Citation>He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer[J]. Mol Cancer, 2019, 18(1):176. https://doi.org/10.1186/s12943-019-1109-9.</Citation></Reference><Reference><Citation>Zhou J, Shi Y, Yang C, et al. &#x3b3;-Glutamylcysteine alleviates insulin resistance and hepatic steatosis by regulating adenylate cyclase and IGF-1R/IRS1/PI3K/Akt signaling pathways[J]. J Nutr Biochem, 2023, 119:109404. https://doi.org/10.1016/j.jnutbio. 2023.109404.</Citation></Reference><Reference><Citation>Xu H, Zhou Y, Liu Y, et al. Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis[J]. J Endocrinol, 2016, 229(2):133-144. https://doi.org/10.1530/JOE-15-0409.</Citation></Reference><Reference><Citation>Chewchinda S, Leakaya N, Sato H, et al. Antidiabetic effects of <i>Maclura cochinchinensis</i>(Lour.)corner heartwood extract[J]. J Tradit Complement Med, 2019, 11(1):68-74. https://doi.org/10. 1016/j.jtcme.2019.10.004.</Citation></Reference><Reference><Citation>Ramachandran V, Saravanan R. Glucose uptake through translocation and activation of GLUT4 in PI3K/Akt signaling pathway by Asiatic acid in diabetic rats[J]. Hum Exp Toxicol, 2015, 34(9):884-893. https://doi.org/10.1177/0960327114561663.</Citation></Reference><Reference><Citation>Masoud Abd El Gayed E, Kamal El Din Zewain S, Ragheb A, et al. Fat mass and obesity-associated gene expression and disease severity in type 2 diabetes mellitus[J]. Steroids, 2021, 174:108897. https://doi.org/10.1016/j.steroids.2021.108897.</Citation></Reference><Reference><Citation>Xie W, Ma LL, Xu YQ, et al. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism[J]. Biochem Biophys Res Commun, 2019, 518(1):120-126. https://doi.org/10. 1016/j.bbrc.2019.08.018.</Citation></Reference><Reference><Citation>Kang LR, Wang C, Yan XC, et al. 1819-P:glypican-4 deletion in &#x3b2;-cells impairs islet architecture and HFD-feeding-associated insulin secretion[J/OL]. Diabetes, 2025, 74(Supplement_1):1819-181 P[2025-03-01]. https://doi.org/10.2337/db25-1819-p.</Citation></Reference><Reference><Citation>Kong L, Zhao Q, Jiang X, et al. Trimethylamine N-oxide impairs &#x3b2;-cell function and glucose tolerance[J]. Nat Commun, 2024, 15:2526. https://doi.org/10.1038/s41467-024-46829-0.</Citation></Reference><Reference><Citation>Sarkar P, Chatterjee D, Bandyopadhyay AR. Effect of MTHFR(rs1801133)and FTO(rs9939609)genetic polymorphisms and obesity in T2DM:a study among Bengalee Hindu caste population of West Bengal, India[J]. Ann Hum Biol, 2021, 48(1):62-65. https://doi.org/10.1080/03014460.2021.1876920.</Citation></Reference><Reference><Citation>Ara&#xfa;jo LS, da Silva MV, da Silva CA, et al. Analysis of serum inflammatory mediators in type 2 diabetic patients and their influence on renal function[J/OL]. PLoS One, 2020, 15(3):e 0229765[2025-03-01]. https://doi.org/10.1371/journal.pone.0229765.</Citation></Reference><Reference><Citation>Kahraman S, De Jesus DF, Wei J, et al. m<sup>6</sup>A mRNA methylation by METTL14 regulates early pancreatic cell differentiation[J]. EMBO J, 2024, 43(22):5445-5468. https://doi. org/10.1038/s44318-024-00213-2.</Citation></Reference><Reference><Citation>Wang J, Yang JL, Zhou PP, et al. Further new gypenosides from Jiaogulan(<i>Gynostemma pentaphyllum</i>)[J]. J Agric Food Chem, 2017, 65(29):5926-5934. https://doi.org/10.1021/acs.jafc. 7b01477.</Citation></Reference><Reference><Citation>Gao D, Zhao M, Qi X, et al. Hypoglycemic effect of <i>Gynostemma pentaphyllum</i> saponins by enhancing the Nrf2 signaling pathway in STZ-inducing diabetic rats[J]. Arch Pharm Res, 2016, 39(2):221-230. https://doi.org/10.1007/s12272-014-0441-2.</Citation></Reference><Reference><Citation>Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs[J]. Expert Opin Drug Saf, 2013, 12(2):153-175. https://doi.org/10.1517/14740338.2013. 752813.</Citation></Reference><Reference><Citation>Nguyen NH, Ha TKQ, Yang JL, et al. Triterpenoids from the genus <i>Gynostemma</i>:Chemistry and pharmacological activities[J]. J Ethnopharmacol, 2021, 268:113574. https://doi.org/10. 1016/j.jep.2020.113574.</Citation></Reference><Reference><Citation>Liu J, Yue Y, Han D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation[J]. Nat Chem Biol, 2014, 10(2):93-95. https://doi. org/10.1038/nchembio.1432.</Citation></Reference><Reference><Citation>Mitsuhashi H, Tsukada Y, Ono K, et al. Urine glycosaminoglycans and heparan sulfate excretions in adult patients with glomerular diseases[J]. Clin Nephrol, 1993, 39(5):231-238.</Citation></Reference><Reference><Citation>Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases[J]. Mol Cell, 2016, 63(2):306-317. https://doi.org/10.1016/j.molcel.2016. 05.041.</Citation></Reference><Reference><Citation>Wu X, Wang W, Fan S, et al. U-shaped association between serum IGF<sub>2</sub>BP<sub>3</sub> and T2DM:a cross-sectional study in Chinese population[J]. J Diabetes, 2023, 15(4):349-361. https://doi.org/10. 1111/1753-0407.13378.</Citation></Reference><Reference><Citation>Xu CL, Tan QY, Yang H, et al. Melatonin enhances spermatogonia activity through promoting KIAA1429-mediated m6A deposition to activate the PI3K/AKT signaling[J]. Reprod Biol, 2022, 22(4):100681. https://doi.org/10.1016/j.repbio.2022.100681.</Citation></Reference><Reference><Citation>Yang Y, Shen F, Huang W, et al. Glucose is involved in the dynamic regulation of m6A in patients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2019, 104(3):665-673. https://doi.org/10.1210/jc.2018-00619.</Citation></Reference><Reference><Citation>Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84. https://doi.org/10.1002/hep.28431.</Citation></Reference><Reference><Citation>Zhang Y, Li L, Chai T, et al. Mulberry leaf multi-components exert hypoglycemic effects through regulation of the PI-3K/Akt insulin signaling pathway in type 2 diabetic rats[J]. J Ethnopharmacol, 2024, 319(Pt 3):117307. https://doi.org/10.1016/j. jep.2023.117307.</Citation></Reference><Reference><Citation>Herman R, Kravos NA, Jensterle M, et al. Metformin and insulin resistance:a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport[J]. Int J Mol Sci, 2022, 23(3):1264. https://doi.org/10.3390/ijms23031264.</Citation></Reference><Reference><Citation>Lee AY, Christensen SM, Duong N, et al. Sirt3 pharmacologically promotes insulin sensitivity through PI<sub>3</sub>/AKT/mTOR and their downstream pathway in adipocytes[J]. Int J Mol Sci, 2022, 23(7):3740. https://doi.org/10.3390/ijms23073740.</Citation></Reference><Reference><Citation>Luo YL, Luo WJ, Cao YN, et al. m6A demethylase FTO/ALKBH5 promotes diabetes-induced endothelial cell dysfunction by negatively regulating lncRNA H19[J]. Exp Mol Pathol, 2025, 143:104970. https://doi.org/10.1016/j.yexmp.2025.104970.</Citation></Reference><Reference><Citation>Zhu S, Jiang L, Liu X, et al. m6A demethylase Fto inhibited macrophage activation and glycolysis in diabetic nephropathy via m6A/Npas2/Hif-1&#x3b1; axis[J/OL]. FASEB J, 2025, 39(2):e 70332[2025-03-01]. https://doi.org/10.1096/fj.202403014R.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41651891</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Bioequivalence assessment between two formulations of a film-coated fixed-dose combination of metformin and vildagliptin&#xa0;(850/50mg) in healthy Tunisian subjects under fed conditions.</ArticleTitle><Pagination><StartPage>5407</StartPage><MedlinePgn>5407</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5407</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-34082-4</ELocationID><Abstract><AbstractText>In Tunisia, bioequivalence studies have been required for generic drug approval since 2008. This study aimed to assess the bioequivalence of vildagliptin and metformin fixed-dose combination (FDC) 850/50&#xa0;mg for a tested (Bi-Galvine) versus the approved reference products (Galvumet). A randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study with a washout period of 7 days to compare metformin/vildagliptin film-coated tablets in 18 healthy Tunisian subjects aged between 18 and 50 years under fed conditions was conducted at the National Center Chalbi Belkahia of Pharmacovigilance. During each period, 20 blood samples were collected from each subject at pre-dosing (0.00) and between 0.25 and 24.00&#xa0;h after dosing. The bioequivalence between the test (T) and reference (R) products required 90% confidence intervals (CIs) for the geometric least square (LS) mean T/R ratio to be within 80-125% for the pharmacokinetic parameters, maximum plasma concentration (C<sub>max</sub>), and Area Under the Curve from zero to 24&#xa0;h (AUC<sub>0-24&#xa0;h</sub>). The 90% CIs of the geometric means of the T/R ratios for C<sub>max</sub> and AUC<sub>0-24&#xa0;h</sub> for metformin were 92.01-102.66% and 93.55-101.80%, respectively; the corresponding results for vildagliptin were 96.03-107.09% and 94.46-101.92%, respectively. Other parameters, such as AUC<sub>0-&#x221e;</sub>, time to maximum concentration (T<sub>max</sub>), and terminal half-life (t<sub>1/2</sub>), were comparable between the test and reference products. Adverse events (AEs), mainly hypoglycemia and loose stools events, were reported without relevant differences between the test and reference products. AEs were generally mild and transient. No severe or serious AEs occurred. The new generic drug product of metformin/vildagliptin FDC 850/50&#xa0;mg demonstrated bioequivalence to the approved product and is therefore expected to provide similar therapeutic effects.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferchichi</LastName><ForeName>Khouloud</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia. kholod.ferchichi@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia. kholod.ferchichi@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia. kholod.ferchichi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaies</LastName><ForeName>Emna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Hammamia</LastName><ForeName>Syrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Jebari</LastName><ForeName>Hanene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daldoul</LastName><ForeName>Mouna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghorbel</LastName><ForeName>Salma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srairi</LastName><ForeName>Semia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guermazi</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Medical Laboratory at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorgi</LastName><ForeName>Yousr</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Medical Laboratory at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutiba</LastName><ForeName>Ilhem</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Medical Laboratory at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouzid</LastName><ForeName>Kahena</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry Medical Laboratory at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbessi</LastName><ForeName>Aimen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmacy at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daghfous</LastName><ForeName>Riadh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Sassi</LastName><ForeName>Mouna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trabelsi</LastName><ForeName>Sameh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>I6B4B2U96P</RegistryNumber><NameOfSubstance UI="D000077597">Vildagliptin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016568">Drugs, Generic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077597" MajorTopicYN="Y">Vildagliptin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016568" MajorTopicYN="N">Drugs, Generic</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioavailability</Keyword><Keyword MajorTopicYN="N">Bioequivalence</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">Tunisia</Keyword><Keyword MajorTopicYN="N">Vildagliptin</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>10</Day><Hour>1</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>7</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>6</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41651891</ArticleId><ArticleId IdType="pmc">PMC12886820</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-34082-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-34082-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mbarki, S. <i>et al.</i> EPIDEMIOLOGIE DU DIABETE SUCRE EN TUNISIE.Etude Hammam Sousse Sahloul heart study (HSHS 2). <i>Tunis Med.</i><b>100</b>(3), 229&#x2013;240 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9387647</ArticleId><ArticleId IdType="pubmed">36005915</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous. Vildagliptin / Metformin Hydrochloride Accord | European Medicines Agency. n.d. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vildagliptin-metformin-hydrochloride-accord [Last accessed: 12/17/2023].</Citation></Reference><Reference><Citation>Anonymous. WMA - The World Medical Association-WMA Declaration of Helsinki &#x2013; Ethical Principles for Medical Research Involving Human Participants. n.d. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki/ [Last accessed: 11/28/2025].</Citation><ArticleIdList><ArticleId IdType="pubmed">39425955</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous &amp; ICH E6 Good Clinical Practice - Scientific Guideline | European Medicines Agency (EMA). (2002). Available from: https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline [Last accessed: 11/28/2025].</Citation></Reference><Reference><Citation>Anonymous. Investigation of Bioequivalence - Scientific Guideline | European Medicines Agency. n.d. Available from: https://www.ema.europa.eu/en/investigation-bioequivalence-scientific-guideline [Last accessed: 12/17/2023].</Citation></Reference><Reference><Citation>Anonymous Compendium.Ch. n.d. Available from: https://compendium.ch/product/1138799-galvumet-cpr-pell-50-850-mg/mpro [Last accessed: 7/22/2024].</Citation></Reference><Reference><Citation>Research, C. DE and. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs &#x2014; General Considerations. FDA; (2020). Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations [Last accessed: 12/17/2023].</Citation></Reference><Reference><Citation>Sen, P. et al. Bioequivalence study of vildagliptin and Metformin fixed dose combinations in healthy volunteers. <i>Indian Practitioner</i>. <b>73</b> (1), 28&#x2013;33 (2020).</Citation></Reference><Reference><Citation>Chow, S-C. &amp; Wang, H. On sample size calculation in bioequivalence trials. <i>J. Pharmacokinet. Pharmacodyn.</i><b>28</b>(2), 155&#x2013;169. 10.1023/A:1011503032353 (2001).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1011503032353</ArticleId><ArticleId IdType="pubmed">11381568</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous &amp; ICH M10 on Bioanalytical Method Validation - Scientific Guideline | European Medicines Agency. n.d. Available from: https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline [Last accessed: 12/17/2023].</Citation></Reference><Reference><Citation>Denney, W., Duvvuri, S. &amp; Buckeridge, C. Simple, automatic noncompartmental analysis: The PKNCA R Package. <i>J. Pharmacokinet. Pharmacodyn.</i><b>42</b>(1), 11&#x2013;107, S65. ISSN 1573&#x2013;8744. 10.1007/s10928-015-9432-2, R package version 0.12.1, (2015). https://github.com/humanpred/pknca</Citation></Reference><Reference><Citation>Bhupathi, C. &amp; Vajjha, V. H. Sample size recommendation for a bioequivalent study. <i>Statistica</i><b>77</b> (1), 65&#x2013;71 (2017).</Citation></Reference><Reference><Citation>Ram&#xed;rez, E. et al. A preliminary model to avoid the overestimation of sample size in bioequivalence studies. <i>Drug Res.</i><b>63</b> (02), 98&#x2013;103. 10.1055/s-0032-1333296 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1333296</ArticleId><ArticleId IdType="pubmed">23427051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, L. et al. Pharmacokinetics and bioequivalence of a generic Fixed-Dose combination tablet of Metformin Hydrochloride/Vildagliptin versus a branded product in healthy Chinese subjects under fed and fasting conditions. <i>Clin. Pharmacol. Drug Dev.</i><b>11</b> (1), 63&#x2013;70. 10.1002/cpdd.992 (2022).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.992</ArticleId><ArticleId IdType="pubmed">34273258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, P. et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. <i>J. Clin. Pharmacol.</i><b>49</b> (1), 39&#x2013;49. 10.1177/0091270008325152 (2009).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270008325152</ArticleId><ArticleId IdType="pubmed">18832295</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnaars, Y. et al. Bioequivalence studies of new generic formulations of vildagliptin and fixed-drug combination of vildagliptin and Metformin versus respective originator products in healthy volunteers. <i>Diabetes Ther.</i><b>13</b> (6), 1215&#x2013;1229. 10.1007/s13300-022-01269-1 (2022).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13300-022-01269-1</ArticleId><ArticleId IdType="pmc">PMC9174400</ArticleId><ArticleId IdType="pubmed">35543870</ArticleId></ArticleIdList></Reference><Reference><Citation>He, Y-L. et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000&#xa0;mg) fixed-dose combination tablet in healthy volunteers. <i>Curr. Med. Res. Opin.</i><b>24</b> (6), 1703&#x2013;1709. 10.1185/03007990802114070 (2008).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007990802114070</ArticleId><ArticleId IdType="pubmed">18471347</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41638409</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3476</ISSN><JournalIssue CitedMedium="Internet"><Volume>692</Volume><PubDate><Year>2026</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>International journal of pharmaceutics</Title><ISOAbbreviation>Int J Pharm</ISOAbbreviation></Journal><ArticleTitle>Development and characterization of metformin hydrochloride hydrogels as potential wound dressings for diabetic foot ulcers.</ArticleTitle><Pagination><StartPage>126638</StartPage><MedlinePgn>126638</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2026.126638</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-5173(26)00086-4</ELocationID><Abstract><AbstractText>Diabetic foot ulcers are a severe complication of diabetes mellitus, characterized by chronicity and high risk of infection. Their effective management requires wound-specific dressings, as no universal system adequately addresses the full spectrum of wounds. Hydrogel dressings offer promising local therapeutic strategies; however, materials combining mechanical robustness, prolonged drug release, and microenvironment modulation remain limited. Herein, we present a rational design strategy for a physically crosslinked, multi-component PVA-based hydrogel membrane incorporating metformin hydrochloride (MET) as the active pharmaceutical ingredient. Although conventionally administered orally, MET has been increasingly recognized for its anti-inflammatory and pro-regenerative properties, supporting its repurposing for localized wound applications. The developed dressings were comprehensively characterized in terms of rheology, pH modulation, morphology (optical microscopy, SEM), mechanical performance, liquid uptake, MET release, cytocompatibility, and in vitro antibacterial and anti-inflammatory activity. An optimized hydrogel formulation based on PVA (Mw&#xa0;&#x223c;&#xa0;195,000&#xa0;Da) and six freeze-thaw cycles (-80&#xa0;&#xb0;C/&#x223c;22&#xa0;&#xb0;C) exhibited high elasticity (&#x3b5;&#xa0;&gt;&#xa0;380%), tensile strength (&#x3c3;&#xa0;&#x223c;&#xa0;0.23&#xa0;MPa), and minimal permanent deformation (&#x3b5;&#xa0;&#x2264;&#xa0;3%). It enabled prolonged MET release over 72&#xa0;h while maintaining a mildly acidic environment (pH&#xa0;&#x223c;&#xa0;5.5-6.3) favorable for wound healing. Compared with commercial drug-free hydrogel dressings, the optimized formulation showed superior mechanical strength, pH-modulating capacity, antibacterial activity against Escherichia coli and Pseudomonas aeruginosa, as well as attenuation of IL-6 expression in LPS-stimulated keratinocytes, indicating anti-inflammatory activity. Collectively, these findings highlight the early-stage potential of MET-loaded solid-sheet hydrogels as multifunctional dressings for chronic, low-exudate diabetic foot ulcers.</AbstractText><CopyrightInformation>Copyright &#xa9; 2026. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf3;rska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krak&#xf3;w, Poland. Electronic address: an.gorska@uj.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurek</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krak&#xf3;w, Poland. Electronic address: mateusz.kurek@uj.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Migda&#x142;</LastName><ForeName>Arkadiusz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krak&#xf3;w, Poland. Electronic address: arkadiusz.migdal1@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudrycka</LastName><ForeName>Maja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacokinetics and Preliminary Toxicology Research, Center for the Development of Therapies for Civilization and Age-Related Diseases, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krak&#xf3;w, Poland. Electronic address: maja.kudrycka@uj.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zem&#x142;a</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 Krak&#xf3;w, Poland. Electronic address: joanna.zemla@ifj.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latacz</LastName><ForeName>Gniewomir</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacokinetics and Preliminary Toxicology Research, Center for the Development of Therapies for Civilization and Age-Related Diseases, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krak&#xf3;w, Poland; Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krak&#xf3;w, Poland. Electronic address: gniewomir.latacz@uj.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lekka</LastName><ForeName>Ma&#x142;gorzata</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 Krak&#xf3;w, Poland. Electronic address: malgorzata.lekka@ifj.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witek</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Microbiology, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland. Electronic address: karolina.witek@uj.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendyk</LastName><ForeName>Aleksander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krak&#xf3;w, Poland. Electronic address: aleksander.mendyk@uj.edu.pl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Pharm</MedlineTA><NlmUniqueID>7804127</NlmUniqueID><ISSNLinking>0378-5173</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetic foot ulcers</Keyword><Keyword MajorTopicYN="N">Hydrogel wound dressings</Keyword><Keyword MajorTopicYN="N">Metformin hydrochloride</Keyword><Keyword MajorTopicYN="N">Physical crosslinking</Keyword><Keyword MajorTopicYN="N">Poly(vinyl alcohol)</Keyword><Keyword MajorTopicYN="N">Prolonged release</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2026</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>5</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>5</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41638409</ArticleId><ArticleId IdType="doi">10.1016/j.ijpharm.2026.126638</ArticleId><ArticleId IdType="pii">S0378-5173(26)00086-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41634845</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2661-801X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>BMC chemistry</Title><ISOAbbreviation>BMC Chem</ISOAbbreviation></Journal><ArticleTitle>Green evaluation of human plasma levels of metformin, linagliptin, and empagliflozin using HPLC and HPTLC methods: a pharmacokinetic study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13065-026-01726-z</ELocationID><Abstract><AbstractText>Two simple, rapid, cost-effective, and environmentally friendly chromatographic methods were developed and validated for the simultaneous determination of metformin (MEF), linagliptin (LIN), and empagliflozin (EMP) in human plasma, with successful application to pharmacokinetic study. Plasma sample preparation was performed using a straightforward protein precipitation technique employing acetonitrile: methanol: trichloroacetic acid (50:49:1, by volume), which provided high extraction recovery and minimal matrix interference. The first method was based on high-performance liquid chromatography with diode array detection (HPLC-DAD) using an ODS Hypersil C18 column and isocratic elution with a mobile phase consisting of acetonitrile, methanol, and phosphate buffer (pH 3) in a ratio of (40:40:20, by volume), at a flow rate of 1.3 mL/min, with detection at 230&#xa0;nm. The second method employed high-performance thin-layer chromatography (HPTLC) with densitometric detection at 225&#xa0;nm, using silica gel 60 F254 plates and n-hexane: methanol: glacial acetic acid (6:3:1, by volume) as the developing system. Excellent linearity was achieved over concentration ranges of 85-1650 ng/mL for MEF, 50-1100 ng/mL for EMP, and 45-950 ng/mL for LIN using the HPLC method, and 500-2800, 100-800, and 50-550 ng/band, respectively, using the HPTLC method, with correlation coefficients exceeding 0.998. The lower limits of quantitation for the HPLC method were 85, 50, and 45 ng/mL for MEF, EMP, and LIN, respectively. Both methods demonstrated satisfactory accuracy, precision, recovery (&gt;&#x2009;92%), stability, and negligible matrix effects in accordance with European Medicines Agency guidelines. The validated methods were successfully applied to a pharmacokinetic study in healthy volunteers, yielding mean Cmax values of 877.5&#x2009;&#xb1;&#x2009;162.2 ng/mL (MEF), 576&#x2009;&#xb1;&#x2009;87.5 ng/mL (EMP), and 680.8&#x2009;&#xb1;&#x2009;7.9 ng/mL (LIN), with Tmax values of 2.42&#x2009;&#xb1;&#x2009;0.38, 1.5&#x2009;&#xb1;&#x2009;0.61, and 5.3&#x2009;&#xb1;&#x2009;0.52&#xa0;h, respectively. The obtained pharmacokinetic parameters were consistent with reported literature, confirming the reliability and clinical applicability of the proposed green bioanalytical methods.</AbstractText><CopyrightInformation>&#xa9; 2026. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sattar</LastName><ForeName>Osama I Abdel</ForeName><Initials>OIA</Initials><AffiliationInfo><Affiliation>Pharmaceutical Analytical Chemistry Dept Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 11751, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abuseada</LastName><ForeName>Hamed H M</ForeName><Initials>HHM</Initials><AffiliationInfo><Affiliation>Pharmaceutical Analytical Chemistry Dept Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 11751, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emara</LastName><ForeName>Mohamed Saleh</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Pharmaceutical Analytical Chemistry Dept Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 11751, Egypt. Mohamed.emara83@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selim</LastName><ForeName>Islam</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pharmaceutical Analytical Chemistry Department Faculty of Pharmacy, Badr University in Cairo (BUC), Badr city, Cairo, 8829, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Faculty of Biotechnology, Badr University in Cairo (BUC), Badr city, Cairo, 8829, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>BMC Chem</MedlineTA><NlmUniqueID>101741142</NlmUniqueID><ISSNLinking>2661-801X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Empagliflozin</Keyword><Keyword MajorTopicYN="N">HPLC</Keyword><Keyword MajorTopicYN="N">Linagliptin</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">Pharmacokinetic</Keyword><Keyword MajorTopicYN="N">Plasma</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and relevant institutional and national guidelines. The study protocol was reviewed and approved by the Ethics Committee of Badr University in Cairo, Egypt (Approval No. BUC-IACUC/PHA/183/A/2025). Six healthy adult male volunteers aged 18&#x2013;45 years were enrolled in the study. All participants were fully informed about the aims, procedures, and potential risks of the study, and written informed consent was obtained from each participant prior to enrollment. Participant anonymity and data confidentiality were strictly maintained throughout the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41634845</ArticleId><ArticleId IdType="doi">10.1186/s13065-026-01726-z</ArticleId><ArticleId IdType="pii">10.1186/s13065-026-01726-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Regional office for Europe. WHO European Regional Obesity Report 2022.</Citation></Reference><Reference><Citation>Moradi-Lakeh M, Forouzanfar MH, El Bcheraoui C, Daoud F, Afshin A, Hanson SW, et al. High fasting plasma glucose, diabetes, and its risk factors in the eastern Mediterranean region, 1990&#x2013;2013: findings from the global burden of disease study 2013. Diabetes Care. 2017;40:22&#x2013;9.</Citation></Reference><Reference><Citation>Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW, et al. Mortality attributable to diabetes in 20&#x2013;79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2020;162:108086.</Citation></Reference><Reference><Citation>Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420&#x2013;8.</Citation></Reference><Reference><Citation>Kiran T, Parvathi P, Kumar JJ. Development and validation of rp-hplc method for the simultaneous estimation of linagliptin, empagliflozin and metformin in solid dosage forms. Asian J Pharm Anal. 2020;10:117&#x2013;24.</Citation></Reference><Reference><Citation>Shah PA, Shrivastav PS, George AJ. Mixed-mode solid phase extraction combined with LC-MS/MS for determination of empagliflozin and linagliptin in human plasma. Microchem J. 2019;145:523&#x2013;31.</Citation></Reference><Reference><Citation>Neumiller JJ. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitu. Ann Pharmacother. 2012;46:358&#x2013;67.</Citation></Reference><Reference><Citation>Nakka S, Gadthey S, Seema A, Marapakala K. Green assessment of stability indicating RP-HPLC method for simultaneous estimation of metformin, empagliflozin, and linagliptin in bulk and fixed dosage forms using AGREE and GAPI tools. Asian J Green Chem. 2020;8:623&#x2013;41.</Citation></Reference><Reference><Citation>Ganorkar AV, Askarkar SS, Gupta KR, Umekar MJ. Validated stability indicating and assay method development of linagliptin in formulation by RP-HPLC using quality by design. Orbit. 2020;12(2):48&#x2013;61.</Citation></Reference><Reference><Citation>Amin AS, Mohamed SF, Abo-Taleb MM. Stability indicating assay method of metformin, linagliptin and Empagliflozinin pharmaceutical dosage form by HPLC method. Egypt J Chem. 2024;67(7):443&#x2013;9.</Citation></Reference><Reference><Citation>Patel IM, Chhalotiya UK, Jani HD, Kansara D, Kachhiya HM, Shah DA. Simultaneous quantification of empagliflozin, linagliptin and metformin hydrochloride in bulk and synthetic mixture by RP&#x2013;LC method. Future J Pharm Sci. 2021;7:182.</Citation></Reference><Reference><Citation>Yadav CH, Mallibabu A. A RP-LC method in gradient mode for combined quantification of Metformin, Linagliptin, and empagliflozin in combination tablets. J Med Chem Sci. 2022;5:1018&#x2013;25.</Citation></Reference><Reference><Citation>Gurrala S, Raj S, Cvs S, Anumolu PD. Quality-by-design approach for chromatographic analysis of metformin, empagliflozin and linagliptin. J Chromatogr Sci. 2022;60(1):68&#x2013;80.</Citation></Reference><Reference><Citation>Shah D, Meshram D, Patel D, Pradhan P, Patel G. Development and validation of green HPTLC method for simultaneous determination of Dapagliflozin and linagliptin in combined dosage form. Bull Pharm Sci Assiut Univ. 2024;47(2):1037&#x2013;48.</Citation></Reference><Reference><Citation>Patel IM, Chhalotiya UK, Jani HD, Kansara D, Shah DA. Densitometric simultaneous estimation of combination of empagliflozin, linagliptin and Metformin hydrochloride used in the treatment of type 2 diabetes mellitus. JPC-J Planar Chromat. 2020;33:109&#x2013;18.</Citation></Reference><Reference><Citation>Elnadi S, Abdalsabour S, Abdalghany MF, Trabik YA. Stability indicating RP-HPLC and spectrophotometric methods for determination of Gliflozins in their mixture with Metformin. J Iran Chem Soc. 2022;19:1723&#x2013;35.</Citation></Reference><Reference><Citation>Majithia RH, Khodadiya A, Patel VB. Spectrophotometric method development and validation for simultaneous estimation of Anagliptin and Metformin HCl by q - absorption ratio method in synthetic mixture. Heliyon. 2020;6(5):e03855.</Citation></Reference><Reference><Citation>Attimarad M, Nair AB, Nagaraja S, Aldhubiab BE, Venugopala KN, Pottathil SJ. Smart UV derivative spectrophotometric methods for simultaneous determination of Metformin and remogliflozin: development, validation and application to the formulation. Indian J Pharm Educ Res. 2021;55:S293-302.</Citation></Reference><Reference><Citation>Shokouhi S, Sohrabi MR. Net analyte signal and radial basis function neural network for development spectrophotometry method for the simultaneous determination of metformin and sitagliptin in anti-diabetic commercial tablet. Optik. 2021;243:167518.</Citation></Reference><Reference><Citation>Derakhshan MS, Sohrabi MR, Davallo MJ. Developed rapid spectrophotometric method for simultaneous quantitative determination of metformin and linagliptin mixture as antidiabetic drugs by artificial intelligence methodology in biological fluid and pharmaceutical sample. Optik. 2021;241:166922.</Citation></Reference><Reference><Citation>Hassasi S, Hassaninejad-Darzi SK, Vahid AJ. Production of copper-graphene nanocomposite as a voltammetric sensor for determination of anti-diabetic metformin using response surface methodology. Microchem J. 2022;172:106877.</Citation></Reference><Reference><Citation>Haq I, Cruz AG, Di Masi S, Cowen T, Allcock NS, Malitesta C, et al. Smart nano-actuators for electrochemical sensing of Metformin in human plasma. Sens Actuators B Chem. 2023;376:132928.</Citation></Reference><Reference><Citation>D&#x2019;Souza M, Dwivedi P, Lokhande R, Anvekar T, Sharma S, D&#x2019;Souza AJ. A simple sensitive and rapid gas chromatography method for detection and quantization of metformin in metformin tablet formulation, by direct injection, using mass detector. Rasa J Chem. 2022;15(1):334&#x2013;42.</Citation></Reference><Reference><Citation>Emam AA, Habib NM, Mahmoud HM, Abdelwhab NS, Abdelrahman MM. Ecofriendly chromatographic methods for determination of co-prescribed drugs, olanzapine and metformin, in rat plasma. Bioanalysis. 2020;12:597&#x2013;613.</Citation></Reference><Reference><Citation>Magdy MA, Ali NW, Taha AA, Elgebaly AM, Farid NF. Different chromatographic methods for determination of alogliptin benzoate, Metformin hydrochloride, and Metformin impurity in bulk and pharmaceutical dosage form. J Sep Sci. 2021;44:833&#x2013;42.</Citation></Reference><Reference><Citation>Patel IM, Chhalotiya UK, Jani HD, Kansara D, Shah DA. Densitometric simultaneous estimation of combination of empagliflozin, linagliptin and Metformin hydrochloride used in the treatment of type 2 diabetes mellitus. J Planar Chromatogr Mod TLC. 2020;33:109&#x2013;18.</Citation></Reference><Reference><Citation>Alkather Z, Hailat M, Al-Shdefat R, Abu Dayyih WJ. Development and validation of HPLC method for five gliptins in pharmaceutical dosage forms in finished marketed products. Curr Pharm Anal. 2021;17:1263&#x2013;71.</Citation></Reference><Reference><Citation>Vankalapati KR, Alegete P, Boodida SJ. Stability-indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of metformin, linagliptin, and empagliflozin in bulk and pharmaceutical dosage form. Biomed Chromatogr. 2021;35:e5019.</Citation></Reference><Reference><Citation>Abou-Omar M, Kenawy M, Youssef A, Alharthi S, Attia M, Mohamed EH. Validation of a novel UPLC-MS/MS method for estimation of metformin and empagliflozin simultaneously in human plasma using freezing lipid precipitation approach and its application to pharmacokinetic study. J Pharm Biomed Anal. 2021;200:114078.</Citation></Reference><Reference><Citation>European Medicines Agency. Guideline on validation of bioanalytical methods. London: Committee for Medicinal Products for Human Use; 2009.</Citation></Reference><Reference><Citation>Mansour FR, Omer KM, P&#x142;otka-Wasylka J. A total scoring system and software for complex modified GAPI (ComplexMoGAPI) application in the assessment of method greenness. Green Anal Chem. 2024;10:100126.</Citation></Reference><Reference><Citation>Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of Metformin. Clin Pharmacokinet. 2011;50:81&#x2013;98.</Citation></Reference><Reference><Citation>Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35:A33&#x2013;42.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41633759</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2125</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>British journal of clinical pharmacology</Title><ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/bcp.70430</ELocationID><Abstract><AbstractText>The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia, epilepsy and anxiety. Additionally, cannabinoids are frequently used for recreational purposes. The evolving legislation surrounding cannabis has added a layer of complexity to the understanding of its pharmacological effects. Societal attitudes shifting towards a more permissive acceptance of cannabis use make it essential to balance individual freedom with public health concerns. While the use of cannabinoids remains a subject of ongoing research, clinical data have shown promise in the treatment of mental health disorders. However, debates and concerns have been raised regarding the potential pharmacokinetic (PK) drug-drug interactions that may occur, involving changes in the absorption, distribution, metabolism and excretion (ADME) of the prescribed drugs. The future prospect of patients having unrestricted access to cannabis requires special attention in case of concurrent use with the common medical treatments they may be receiving for a cardiovascular or metabolic disease or with medications related to the treatment of psychiatric disorders. This comprehensive review aims to critically discuss the main PK interactions of major cannabinoids (tetrahydrocannabinol, cannabidiol, cannabinol, cannabichromene and cannabigerol) in relation to the drugs prescribed in neuropathic pain, depression, anxiety, schizophrenia, epilepsy and cancer, as well as with the most common cardiometabolic disease treatments such as statins, beta-blockers, warfarin, insulin analogues and metformin.</AbstractText><CopyrightInformation>&#xa9; 2026 The Author(s). British Journal of Clinical Pharmacology published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papakyriakopoulou</LastName><ForeName>Paraskevi</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0566-0713</Identifier><AffiliationInfo><Affiliation>Laboratory of Biopharmaceutics and Pharmacokinetics, Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valsami</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2395-6844</Identifier><AffiliationInfo><Affiliation>Laboratory of Biopharmaceutics and Pharmacokinetics, Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismailos</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Experimental, Training and Research Center ELPEN, ELPEN Pharmaceuticals, Attica, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Pharmacol</MedlineTA><NlmUniqueID>7503323</NlmUniqueID><ISSNLinking>0306-5251</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">cardiometabolic diseases</Keyword><Keyword MajorTopicYN="N">central nervous system</Keyword><Keyword MajorTopicYN="N">drug interactions</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>3</Day><Hour>20</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41633759</ArticleId><ArticleId IdType="doi">10.1002/bcp.70430</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Legare CA, Raup&#x2010;Konsavage WM, Vrana KE. Therapeutic potential of cannabis, cannabidiol, and cannabinoid&#x2010;based pharmaceuticals. Pharmacology. 2022;107(3&#x2013;4):131&#x2010;149. doi:10.1159/000521683</Citation></Reference><Reference><Citation>Scherma M, Muntoni AL, Riedel G, Fratta W, Fadda P. Cannabinoids and their therapeutic applications in mental disorders. Dialogues Clin Neurosci. 2020 Sep;22(3):271&#x2010;279. doi:10.31887/DCNS.2020.22.3/pfadda</Citation></Reference><Reference><Citation>Vu&#x10d;kovi&#x107; S, Srebro D, Vujovi&#x107; KS, Vu&#x10d;eti&#x107; &#x10c;, Prostran M. Cannabinoids and pain: new insights from old molecules. Front Pharmacol. 2018;9:1259. doi:10.3389/fphar.2018.01259</Citation></Reference><Reference><Citation>Devinsky O, Kraft K, Rusch L, Fein M, Leone&#x2010;Bay A. Improved bioavailability with dry powder cannabidiol inhalation: a phase 1 clinical study. J Pharm Sci. 2021 Dec;110(12):3946&#x2010;3952. doi:10.1016/j.xphs.2021.08.012</Citation></Reference><Reference><Citation>Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox&#x2010;Gastaut syndrome (GWPCARE4): a randomised, double&#x2010;blind, placebo&#x2010;controlled phase 3 trial. Lancet. 2018;391(10125):1085&#x2010;1096. doi:10.1016/S0140&#x2010;6736(18)30136&#x2010;3</Citation></Reference><Reference><Citation>Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018 Aug;27(4):327&#x2010;335. doi:10.1017/S2045796018000239</Citation></Reference><Reference><Citation>Oberbarnscheidt T, Miller NS. The impact of cannabidiol on psychiatric and medical conditions. J Clin Med Res. 2020 Jul;12(7):393&#x2010;403. doi:10.14740/jocmr4159</Citation></Reference><Reference><Citation>Peyravian N, Deo S, Daunert S, Jimenez JJ. Cannabidiol as a novel therapeutic for immune modulation. Immunotargets Ther. 2020;9:131&#x2010;140. doi:10.2147/ITT.S263690</Citation></Reference><Reference><Citation>Repka MA, ElSohly MA, Munjal M, Ross SA. Temperature stability and bioadhesive properties of delta9&#x2010;tetrahydrocannabinol incorporated hydroxypropylcellulose polymer matrix systems. Drug Dev Ind Pharm. 2006;32(1):21&#x2010;32. doi:10.1080/03639040500387914</Citation></Reference><Reference><Citation>Corroon J. Cannabinol and sleep: separating fact from fiction. Cannabis Cannabinoid Res. 2021 Oct;6(5):366&#x2010;371. doi:10.1089/can.2021.0006</Citation></Reference><Reference><Citation>Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9&#x2010;tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol. 2005;168:657&#x2010;690. doi:10.1007/3&#x2010;540&#x2010;26573&#x2010;2_23</Citation></Reference><Reference><Citation>Kaul M, Zee PC, Sahni AS. Effects of cannabinoids on sleep and their therapeutic potential for sleep disorders. Neurotherapeutics. 2021 Jan;18(1):217&#x2010;227. doi:10.1007/s13311&#x2010;021&#x2010;01013&#x2010;w</Citation></Reference><Reference><Citation>Hong M, Kim J&#x2010;H, Han J&#x2010;H, et al. In vitro and in vivo anti&#x2010;inflammatory potential of cannabichromene isolated from hemp. Plants. 2023;12(23):3966.</Citation></Reference><Reference><Citation>Roy P, Maturano J, Hasdemir H, et al. Elucidating the mechanism of metabolism of cannabichromene by human cytochrome P450s. J Nat Prod. 2024;87(4):639&#x2010;651. doi:10.1021/acs.jnatprod.3c00336</Citation></Reference><Reference><Citation>European Pharmacopoeia Commission (EPC), Cannabis flower (Monograph 3028), Publication Date: 2024 (Expected release in January 2024 with publication of supplement 11.5).</Citation></Reference><Reference><Citation>Chambers J, Keyhani S, Ling PM, et al. Perceptions of safety of daily cannabis vs tobacco smoking and secondhand smoke exposure, 2017&#x2010;2021. JAMA Netw Open. 2023 Aug;6(8):e2328691. doi:10.1001/jamanetworkopen.2023.28691</Citation></Reference><Reference><Citation>Cohen K, Weizman A, Weinstein A. Positive and negative effects of cannabis and cannabinoids on health. Clin Pharmacol Ther. 2019 May;105(5):1139&#x2010;1147. doi:10.1002/cpt.1381</Citation></Reference><Reference><Citation>DeFilippis EM, Bajaj NS, Singh A, et al. Marijuana use in patients with cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol. 2020;28(3):320&#x2010;332. doi:10.1016/j.jacc.2019.11.025</Citation></Reference><Reference><Citation>Lopera V, Rodr&#xed;guez A, Amariles P. Clinical relevance of drug interactions with cannabis: a systematic review. J Clin Med. 2022;11(5):1154. doi:10.3390/jcm11051154</Citation></Reference><Reference><Citation>Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Am J Med. 2013 Jul;126(7):583&#x2010;589. doi:10.1016/j.amjmed.2013.03.002</Citation></Reference><Reference><Citation>Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co&#x2010;administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018 Sep;43(10):2046&#x2010;2055. doi:10.1038/s41386&#x2010;018&#x2010;0011&#x2010;2</Citation></Reference><Reference><Citation>Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug&#x2010;drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015 Aug;56(8):1246&#x2010;1251. doi:10.1111/epi.13060</Citation></Reference><Reference><Citation>Brzozowska NI, de Tonnerre EJ, Li KM, et al. The differential binding of antipsychotic drugs to the ABC transporter P&#x2010;glycoprotein predicts cannabinoid&#x2010;antipsychotic drug interactions. Neuropsychopharmacology. 2017 Oct;42(11):2222&#x2010;2231. doi:10.1038/npp.2017.50</Citation></Reference><Reference><Citation>Radwan MM, Chandra S, Gul S, ElSohly MA. Cannabinoids, phenolics, terpenes and alkaloids of cannabis. Molecules. 2021;26(9):2774. doi:10.3390/molecules26092774</Citation></Reference><Reference><Citation>Chayasirisobhon S. Mechanisms of action and pharmacokinetics of cannabis. Perm J. 2020;25:1&#x2010;3. doi:10.7812/TPP/19.200</Citation></Reference><Reference><Citation>Poyatos L, P&#xe9;rez&#x2010;Acevedo AP, Papaseit E, et al. Oral administration of cannabis and &#x394;&#x2010;9&#x2010;tetrahydrocannabinol (THC) preparations: a systematic review. Medicina (Kaunas). 2020;56(6):309. doi:10.3390/medicina56060309</Citation></Reference><Reference><Citation>Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770&#x2010;1804. doi:10.1002/cbdv.200790152</Citation></Reference><Reference><Citation>Foster BC, Abramovici H, Harris CS. Cannabis and cannabinoids: kinetics and interactions. Am J Med. 2019 Nov;132(11):1266&#x2010;1270. doi:10.1016/j.amjmed.2019.05.017</Citation></Reference><Reference><Citation>Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018 Nov;84(11):2477&#x2010;2482. doi:10.1111/bcp.13710</Citation></Reference><Reference><Citation>Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7(4):149&#x2010;156.</Citation></Reference><Reference><Citation>Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Test Anal. 2017 Jun;9(6):905&#x2010;915. doi:10.1002/dta.2092</Citation></Reference><Reference><Citation>Lunn S, Diaz P, O'Hearn S, et al. Human pharmacokinetic parameters of orally administered &#x394;9&#x2010;tetrahydrocannabinol capsules are altered by fed versus fasted conditions and sex differences. Cannabis Cannabinoid Res. 2019 Dec;4(4):255&#x2010;264. doi:10.1089/can.2019.0037</Citation></Reference><Reference><Citation>Hlo&#x17e;ek T, Uttl L, Kade&#x159;&#xe1;bek L, et al. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol. 2017 Dec;27(12):1223&#x2010;1237. doi:10.1016/j.euroneuro.2017.10.037</Citation></Reference><Reference><Citation>Nasrin S, Watson CJW, Perez&#x2010;Paramo YX, Lazarus P. Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis&#x2010;drug interactions. Drug Metab Dispos. 2021b Dec;49(12):1070&#x2010;1080. doi:10.1124/dmd.121.000442</Citation></Reference><Reference><Citation>Millar SA, Stone NL, Yates AS, O'Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365. doi:10.3389/fphar.2018.01365</Citation></Reference><Reference><Citation>Stott CG, White L, Wright S, Wilbraham D, Guy GW. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013b Apr;69(4):825&#x2010;834. doi:10.1007/s00228&#x2010;012&#x2010;1393&#x2010;4</Citation></Reference><Reference><Citation>Batinic A, Sutlovic D, Kuret S, et al. Differences in plasma cannabidiol concentrations in women and men: a randomized, placebo&#x2010;controlled, crossover study. Int J Mol Sci. 2023;24(12):10273. doi:10.3390/ijms241210273</Citation></Reference><Reference><Citation>Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. Single&#x2010;dose kinetics of deuterium&#x2010;labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom. 1986 Feb;13(2):77&#x2010;83. doi:10.1002/bms.1200130206</Citation></Reference><Reference><Citation>Child RB, Tallon MJ. Cannabidiol (CBD) dosing: plasma pharmacokinetics and effects on accumulation in skeletal muscle, liver and adipose tissue. Nutrients. 2022;14(10):2101. doi:10.3390/nu14102101</Citation></Reference><Reference><Citation>Greger J, Bates V, Mechtler L, Gengo F. A review of cannabis and interactions with anticoagulant and antiplatelet agents. J Clin Pharmacol. 2019;60:432&#x2010;438. doi:10.1002/jcph.1557</Citation></Reference><Reference><Citation>Russo EB, Marcu J. Cannabis pharmacology: the usual suspects and a few promising leads. Adv Pharmacol. 2017;67&#x2010;134. doi:10.1016/bs.apha.2017.03.004</Citation></Reference><Reference><Citation>Maioli C, Mattoteia D, Amin HIM, Minassi A, Caprioglio D. Cannabinol: history, syntheses, and biological profile of the greatest "minor" cannabinoid. Plants (Basel). 2022;11(28):2896. doi:10.3390/plants11212896</Citation></Reference><Reference><Citation>Rhee MH, Vogel Z, Barg J, et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem. 1997 Sep;40(20):3228&#x2010;3233. doi:10.1021/jm970126f</Citation></Reference><Reference><Citation>Yamamoto I, Watanabe K, Kuzuoka K, Narimatsu S, Yoshimura H. The pharmacological activity of cannabinol and its major metabolite, 11&#x2010;hydroxycannabinol. Chem Pharm Bull(Tokyo). 1987 May;35(5):2144&#x2010;2147. doi:10.1248/cpb.35.2144</Citation></Reference><Reference><Citation>Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non&#x2010;psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009 Oct;30(10):515&#x2010;527. doi:10.1016/j.tips.2009.07.006</Citation></Reference><Reference><Citation>Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019;60(11):2224&#x2010;2234. doi:10.1111/epi.16355</Citation></Reference><Reference><Citation>Doohan PT, Oldfield LD, Arnold JC, Anderson LL. Cannabinoid interactions with cytochrome P450 drug metabolism: a full&#x2010;spectrum characterization. AAPS J. 2021 Jun;23(4):91. doi:10.1208/s12248&#x2010;021&#x2010;00616&#x2010;7</Citation></Reference><Reference><Citation>Chen X, Unadkat JD, Mao Q. Tetrahydrocannabinol and its major metabolites are not (or are poor) substrates or inhibitors of human P&#x2010;glycoprotein [ATP&#x2010;binding cassette (ABC) B1] and breast cancer resistance protein (ABCG2). Drug Metab Dispos. 2021 Oct;49(10):910&#x2010;918. doi:10.1124/dmd.121.000505</Citation></Reference><Reference><Citation>Bansal S, Paine MF, Unadkat JD. Comprehensive predictions of cytochrome P450 (P450)&#x2010;mediated in vivo cannabinoid&#x2010;drug interactions based on reversible and time&#x2010;dependent P450 inhibition in human liver microsomes. Drug Metab Dispos. 2022;50(4):351&#x2010;360. doi:10.1124/dmd.121.000734</Citation></Reference><Reference><Citation>Etchart MG, Anderson LL, Ametovski A, et al. In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. Eur J Pharmacol. 2022;922:174836. doi:10.1016/j.ejphar.2022.174836</Citation></Reference><Reference><Citation>Court MH, Mealey KL, Burke NS, Jimenez TP, Zhu Z, Wakshlag JJ. Cannabidiol and cannabidiolic acid: preliminary in vitro evaluation of metabolism and drug&#x2010;drug interactions involving canine cytochrome P&#x2010;450, UDP&#x2010;glucuronosyltransferase, and P&#x2010;glycoprotein. J Vet Pharmacol Ther. 2024 Jan;47(1):1&#x2010;13. doi:10.1111/jvp.13403</Citation></Reference><Reference><Citation>Coates S, Bardhi K, Lazarus P. Cannabinoid&#x2010;induced inhibition of morphine glucuronidation and the potential for in vivo drug&#x2010;drug interactions. Pharmaceutics. 2024;16(3):418. doi:10.3390/pharmaceutics16030418</Citation></Reference><Reference><Citation>Mkabayi L, Viljoen Z, Krause RWM, Lobb KA, Pletschke BI, Frost CL. Inhibitory effects of selected cannabinoids against dipeptidyl peptidase IV, an enzyme linked to type 2 diabetes. Heliyon. 2023;10(1):e23289. doi:10.1016/j.heliyon.2023.e23289</Citation></Reference><Reference><Citation>Anderson LL, Etchart MG, MacNair L, et al. In vitro screening of three commercial cannabis&#x2010;based products on ATP&#x2010;binding cassette and solute&#x2010;carrier transporter function. Cannabis Cannabinoid Res. 2022;7(3):304&#x2010;317. doi:10.1089/can.2020.0053.</Citation></Reference><Reference><Citation>Klein C, Karanges E, Spiro A, et al. Cannabidiol potentiates &#x394;9&#x2010;tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl). 2011;218(2):443&#x2010;457. doi:10.1007/s00213&#x2010;011&#x2010;2342&#x2010;0</Citation></Reference><Reference><Citation>Brzozowska N, Li KM, Wang XS, et al. ABC transporters P&#x2010;gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ. 2016 May;4(26):e2081. doi:10.7717/peerj.2081</Citation></Reference><Reference><Citation>Todd SM, Arnold JC. Neural correlates of interactions between cannabidiol and &#x394;9&#x2010;tetrahydrocannabinol in mice: implications for medical cannabis. Br J Pharmacol. 2016;173(1):53&#x2010;65. doi:10.1111/bph.13333</Citation></Reference><Reference><Citation>Atwal N, Casey SL, Mitchell VA, Vaughan CW. THC and gabapentin interactions in a mouse neuropathic pain model. Neuropharmacology. 2019;144:115&#x2010;121. doi: 10.1016/j.neuropharm.2018.10.006</Citation></Reference><Reference><Citation>Ewing LE, McGill MR, Yee EU, et al. Paradoxical patterns of sinusoidal obstruction syndrome&#x2010;like liver injury in aged female CD&#x2010;1 mice triggered by cannabidiol&#x2010;rich cannabis extract and acetaminophen co&#x2010;administration. Molecules. 2019;24(12):2256. doi:10.3390/molecules24122256</Citation></Reference><Reference><Citation>Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Arch Oral Biol. 2019 Aug;104:33&#x2010;39. doi:10.1016/j.archoralbio.2019.05.028</Citation></Reference><Reference><Citation>Izgelov D, Domb AJ, Hoffman A. The effect of piperine on oral absorption of cannabidiol following acute vs. chronic administration. Eur J Pharm Sci. 2020;148:105313. doi:10.1016/j.ejps.2020.105313</Citation></Reference><Reference><Citation>Uttl L, Hlo&#x17e;ek T, Mare&#x161; P, P&#xe1;len&#xed;&#x10d;ek T, Kubov&#xe1; H. Anticonvulsive effects and pharmacokinetic profile of cannabidiol (CBD) in the pentylenetetrazol (PTZ) or N&#x2010;methyl&#x2010;D&#x2010;aspartate (NMDA) models of seizures in infantile rats. Int J Mol Sci. 2021;23(1):94. doi:10.3390/ijms23010094</Citation></Reference><Reference><Citation>Doran CE, McGrath S, Bartner LR, Thomas B, Cribb AE, Gustafson DL. Drug&#x2010;drug interaction between cannabidiol and phenobarbital in healthy dogs. Am J Vet Res. 2021;83(1):86&#x2010;94. doi:10.2460/ajvr.21.08.0120</Citation></Reference><Reference><Citation>V&#xe1;zquez M, Guevara N, Maldonado C, Guido PC, Schaiquevich P. Potential pharmacokinetic drug&#x2010;drug interactions between cannabinoids and drugs used for chronic pain. Biomed Res Int. 2020;2020:3902740. doi:10.1155/2020/3902740</Citation></Reference><Reference><Citation>Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. 2021 Sep;374(8):n2040. doi:10.1136/bmj.n2040</Citation></Reference><Reference><Citation>Romero&#x2010;Sandoval EA, Kolano AL, Alvarado&#x2010;V&#xe1;zquez PA. Cannabis and cannabinoids for chronic pain. Curr Rheumatol Rep. 2017;19:67. doi:10.1007/s11926&#x2010;017&#x2010;0693&#x2010;1</Citation></Reference><Reference><Citation>Bialas P, B&#xf6;ttge&#x2010;Wolpers C, Fitzcharles MA, et al. Cannabis use disorder in patients with chronic pain: overestimation and underestimation in a cross&#x2010;sectional observational study in 3 German pain management centres. Pain. 2023 Jun;164(6):1303&#x2010;1311. doi:10.1097/j.pain.0000000000002817</Citation></Reference><Reference><Citation>Wilson M, Finlay M, Orr M, et al. Engagement in online pain self&#x2010;management improves pain in adults on medication assisted behavioral treatment for opioid use disorders. Addict Behav. 2018;86:130&#x2010;137. doi:10.1016/j.addbeh.2018.04.019</Citation></Reference><Reference><Citation>Clem SN, Bigand TL, Wilson M. Cannabis use motivations among adults prescribed opioids for pain versus opioid addiction. Pain Manag Nurs. 2020 Feb;21(1):43&#x2010;47. doi:10.1016/j.pmn.2019.06.009</Citation></Reference><Reference><Citation>Gong L, Stamer UM, Tzvetkov MV, Altman RB, Klein TE. PharmGKB summary: tramadol pathway. Pharmacogenet Genomics. 2014 Jul;24(7):374&#x2010;380. doi:10.1097/FPC.0000000000000057</Citation></Reference><Reference><Citation>Cu&#xf1;etti L, Oricchio F, V&#xe1;zquez M, et al. Drug&#x2010;drug interaction between cannabidiol, cyclosporine, and mycophenolate mofetil: a case report. Transplant Proc. 2024;56(1):252&#x2010;256. doi:10.1016/j.transproceed.2023.11.013</Citation></Reference><Reference><Citation>Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double&#x2010;blind, placebo&#x2010;controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018 Nov;32(11):1053&#x2010;1067. doi:10.1007/s40263&#x2010;018&#x2010;0578&#x2010;5</Citation></Reference><Reference><Citation>Bindler RJ, Watson CJW, Lyons AJ, et al. Drug&#x2010;drug interaction between orally administered hydrocodone&#x2010;acetaminophen and inhalation of cannabis smoke: a case report. Hosp Pharm. 2022 Aug;57(4):518&#x2010;525. doi:10.1177/00185787211061374</Citation></Reference><Reference><Citation>Stanciu CN, Brunette MF, Teja N, Budney AJ. Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: a systematic review. Psychiatr Serv. 2021 Apr;72(4):429&#x2010;436. doi:10.1176/appi.ps.202000189</Citation></Reference><Reference><Citation>Reuveni N, Carlson CA, Schwartz S, Meter D, Barrett TS, Freeman SM. The antidepressant and anxiolytic effects of cannabinoids in chronic unpredictable stress: a preclinical systematic review and meta&#x2010;analysis. Transl Psychiatry. 2022 May;12(1):217. doi:10.1038/s41398&#x2010;022&#x2010;01967&#x2010;1</Citation></Reference><Reference><Citation>Vaughn SE, Strawn JR, Poweleit EA, Sarangdhar M, Ramsey LB. The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacologic considerations. J Pers Med. 2021;11(7):615. doi:10.3390/jpm11070615</Citation></Reference><Reference><Citation>Bahji A, Meyyappan AC, Hawken ER. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: a systematic review &amp; meta&#x2010;analysis. J Psychiatr Res. 2020 Oct;129:257&#x2010;264. doi:10.1016/j.jpsychires.2020.07.030</Citation></Reference><Reference><Citation>Purcell C, Davis A, Moolman N, Taylor SM. Reduction of benzodiazepine use in patients prescribed medical cannabis. Cannabis Cannabinoid Res. 2019 Sep;4(3):214&#x2010;218. doi:10.1089/can.2018.0020</Citation></Reference><Reference><Citation>Balachandran P, Elsohly M, Hill KP. Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review. J Gen Intern Med. 2021 Jul;36(7):2074&#x2010;2084. doi:10.1007/s11606&#x2010;020&#x2010;06504&#x2010;8</Citation></Reference><Reference><Citation>Khalid S, Rasool MF, Imran I, et al. A physiologically based pharmacokinetic model for predicting diazepam pharmacokinetics after intravenous, oral, intranasal, and rectal applications. Pharmaceutics. 2021;13(15):1480. doi:10.3390/pharmaceutics13091480</Citation></Reference><Reference><Citation>Deniz S, Sancar M, Okuyan B, et al. Determination of CYP2C19 polymorphism, side effects, and medication adherence in patients who have utilized selective serotonin reuptake inhibitors. Klinik Psikofarmakoloji B&#xfc;lteni&#x2010;Bulletin of Clinical Psychopharmacology. 2016;26(2):152&#x2010;160. doi:10.5455/bcp.20151003060610</Citation></Reference><Reference><Citation>Dyck GJB, Maayah ZH, Eurich DT, Dyck JRB. Understanding the potential benefits of cannabidiol for patients with schizophrenia: a narrative review. Schizophr Bull Open. 2022;3(1):sgab053. doi:10.1093/schizbullopen/sgab053</Citation></Reference><Reference><Citation>Arendt M, Rosenberg R, Foldager L, Perto G, Munk&#x2010;J&#xf8;rgensen P. Cannabis&#x2010;induced psychosis and subsequent schizophrenia&#x2010;spectrum disorders: follow&#x2010;up study of 535 incident cases. Br J Psychiatry. 2005;187(6):510&#x2010;515. doi:10.1192/bjp.187.6.510</Citation></Reference><Reference><Citation>Little R, D'Mello D. A cannabinoid hypothesis of schizophrenia: pathways to psychosis. Innov Clin Neurosci. 2022;19(7&#x2013;9):38&#x2010;43.</Citation></Reference><Reference><Citation>Perera T, Webler R. Cannabis&#x2010;induced psychosis and an antipsychotic&#x2010;induced seizure: a case report. Prim Care Companion CNS Disord. 2017;19(1). doi:10.4088/PCC.16l01993</Citation></Reference><Reference><Citation>Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of &#x394;9&#x2010;tetrahydrocannabinol on the dopamine system. Nature. 2016;539(17):369&#x2010;377. doi:10.1038/nature20153</Citation></Reference><Reference><Citation>Robison AJ, Thakkar KN, Diwadkar VA. Cognition and reward circuits in schizophrenia: synergistic, not separate. Biol Psychiatry. 2020;87(1):204&#x2010;214. doi:10.1016/j.biopsych.2019.09.021</Citation></Reference><Reference><Citation>Batalla A, Janssen H, Gangadin SS, Bossong MG. The potential of cannabidiol as a treatment for psychosis and addiction: who benefits most? A systematic review. J Clin Med. 2019;8(7):1058. doi:10.3390/jcm8071058</Citation></Reference><Reference><Citation>Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2009 Nov;23(8):979&#x2010;983. doi:10.1177/0269881108096519</Citation></Reference><Reference><Citation>McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225&#x2010;231. doi:10.1176/appi.ajp.2017.17030325</Citation></Reference><Reference><Citation>Boggs DL, Surti T, Gupta A, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl). 2018;235(7):1923&#x2010;1932. doi:10.1007/s00213&#x2010;018&#x2010;4885&#x2010;9</Citation></Reference><Reference><Citation>Makiol C, Kluge M. Remission of severe, treatment&#x2010;resistant schizophrenia following adjunctive cannabidiol. Aust N Z J Psychiatry. 2019 Mar;53(3):262. doi:10.1177/0004867418815982</Citation></Reference><Reference><Citation>Abu&#x2010;Sawwa R, Scutt B, Park Y. Emerging use of Epidiolex (cannabidiol) in epilepsy. J Pediatr Pharmacol Ther. 2020;25(6):485&#x2010;499. doi:10.5863/1551&#x2010;6776&#x2010;25.6.485</Citation></Reference><Reference><Citation>Saito VM, Rezende RM, Teixeira AL. Cannabinoid modulation of neuroinflammatory disorders. Curr Neuropharmacol. 2012;10(2):159&#x2010;166. doi:10.2174/157015912800604515</Citation></Reference><Reference><Citation>Thornton C, Dickson KE, Carty DR, Ashpole NM, Willett KL. Cannabis constituents reduce seizure behavior in chemically&#x2010;induced and scn1a&#x2010;mutant zebrafish. Epilepsy Behav. 2020 Sep;110:107152. doi:10.1016/j.yebeh.2020.107152</Citation></Reference><Reference><Citation>Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia. 2020 Jun;61(6):1082&#x2010;1089. doi:10.1111/epi.16542</Citation></Reference><Reference><Citation>Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox&#x2010;Gastaut syndrome. N Engl J Med. 2018;378(17):1888&#x2010;1897. doi:10.1056/NEJMoa1714631</Citation></Reference><Reference><Citation>Devinsky O, Thiele EA, Wright S, et al. Cannabidiol efficacy independent of clobazam: meta&#x2010;analysis of four randomized controlled trials. Acta Neurol Scand. 2020 Dec;142(6):531&#x2010;540. doi:10.1111/ane.13305</Citation></Reference><Reference><Citation>Groeneveld GJ, Martin JH. Parasitic pharmacology: a plausible mechanism of action for cannabidiol. Br J Clin Pharmacol. 2020 Feb;86(2):189&#x2010;191. doi:10.1111/bcp.14028</Citation></Reference><Reference><Citation>Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP, UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586&#x2010;1592. doi:10.1111/epi.13852</Citation></Reference><Reference><Citation>Wray L, Berwaerts J, Critchley D, et al. Pharmacokinetic drug&#x2010;drug interaction with coadministration of cannabidiol and everolimus in a phase 1 healthy volunteer trial. Clin Pharmacol Drug Dev. 2023 Sep;12(9):911&#x2010;919. doi:10.1002/cpdd.1262</Citation></Reference><Reference><Citation>Lattanzi S, Brigo F, Trinka E, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta&#x2010;analysis. Drugs. 2018 Nov;78(17):1791&#x2010;1804. doi:10.1007/s40265&#x2010;018&#x2010;0992&#x2010;5</Citation></Reference><Reference><Citation>Watkins PB, Church RJ, Li J, Knappertz V. Cannabidiol and abnormal liver chemistries in healthy adults: results of a phase I clinical trial. Clin Pharmacol Ther. 2021 May;109(5):1224&#x2010;1231. doi:10.1002/cpt.2071</Citation></Reference><Reference><Citation>Hardy JR, Greer RM, Pelecanos AM, et al. Medicinal cannabis for symptom control in advanced cancer: a double&#x2010;blind, placebo&#x2010;controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol. Support Care Cancer. 2025 Jul;33(8):715. doi:10.1007/s00520&#x2010;025&#x2010;09763&#x2010;5</Citation></Reference><Reference><Citation>Solomon JM, Ajewole VB, Schneider AM, Sharma M, Bernicker EH. Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center. J Oncol Pharm Pract. 2019 Oct;25(7):1564&#x2010;1569. doi:10.1177/1078155218798150</Citation></Reference><Reference><Citation>Weiss MC, Hibbs JE, Buckley ME, et al. A Coala&#x2010;T&#x2010;cannabis survey study of breast cancer patients' use of cannabis before, during, and after treatment. Cancer. 2022;128(1):160&#x2010;168. doi:10.1002/cncr.33906</Citation></Reference><Reference><Citation>Aviram J, Lewitus GM, Vysotski Y, et al. Short&#x2010;term medical cannabis treatment regimens produced beneficial effects among palliative cancer patients. Pharmaceuticals (Basel). 2020;13(30):435. doi:10.3390/ph13120435</Citation></Reference><Reference><Citation>Likar R, Koestenberger M, Stultschnig M, Nahler G. Concomitant treatment of malignant brain tumours with CBD&#x2014;a case series and review of the literature. Anticancer Res. 2019 Oct;39(10):5797&#x2010;5801. doi:10.21873/anticanres.13783</Citation></Reference><Reference><Citation>Dall'Stella PB, Docema MFL, Maldaun MVC, Feher O, Lancellotti CLP. Case report: clinical outcome and image response of two patients with secondary high&#x2010;grade glioma treated with chemoradiation, PCV, and cannabidiol. Front Oncol. 2019;8:643. doi:10.3389/fonc.2018.00643</Citation></Reference><Reference><Citation>Liew KL, Capuano E, Yung B. Lung cancer patient who had declined conventional cancer treatment: could the self&#x2010;administration of 'CBD oil' be contributing to the observed tumour regression? BMJ Case Rep. 2021 Oct;14(10):e244195. doi:10.1136/bcr&#x2010;2021&#x2010;244195</Citation></Reference><Reference><Citation>Sul&#xe9;&#x2010;Suso J, Watson NA, van Pittius DG, Jegannathen A. Striking lung cancer response to self&#x2010;administration of cannabidiol: a case report and literature review. SAGE Open Med Case Rep. 2019;7:2050313X19832160. doi:10.1177/2050313X19832160</Citation></Reference><Reference><Citation>Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. J Thorac Dis. 2017 Jul;9(7):2079&#x2010;2092. doi:10.21037/jtd.2017.06.104</Citation></Reference><Reference><Citation>Brown JD, Winterstein AG. Potential adverse drug events and drug&#x2010;drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019;8(7):989. doi:10.3390/jcm8070989</Citation></Reference><Reference><Citation>Sajdeya R, Jugl S, Cook R, Brown JD, Goodin A. Clinical considerations for cannabis use and cardiovascular health. Med Cannabis Cannabinoids. 2022 Sep;5(1):120&#x2010;127. doi:10.1159/000526731</Citation></Reference><Reference><Citation>Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Potteg&#xe5;rd A. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):28&#x2010;31. doi:10.1111/bcpt.13152</Citation></Reference><Reference><Citation>Thomas TF, Metaxas ES, Nguyen T, et al. Case report: medical cannabis&#x2010;warfarin drug&#x2010;drug interaction. J Cannabis Res. 2022 Jan;4(1):6. doi:10.1186/s42238&#x2010;021&#x2010;00112&#x2010;x</Citation></Reference><Reference><Citation>Ngueta G, Ndjaboue R. Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults. J Diabetes. 2020 Jan;12(1):38&#x2010;47. doi:10.1111/1753&#x2010;0407.12958</Citation></Reference><Reference><Citation>Ali Montoya&#x2010;Alatriste C, Alarcon&#x2010;Aguilar FJ. Cannabis and cannabinoids as an alternative remedy in metabolic syndrome. Braz J Pharm Sci. 2022;58:e20161. doi:10.1590/s2175&#x2010;97902022e20161</Citation></Reference><Reference><Citation>Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double&#x2010;blind, placebo&#x2010;controlled, parallel group pilot study. Diabetes Care. 2016 Oct;39(10):1777&#x2010;1786. doi:10.2337/dc16&#x2010;0650</Citation></Reference><Reference><Citation>Ben&#x2010;Menachem E, Gunning B, Arenas Cabrera CM, et al. A phase II randomized trial to explore the potential for pharmacokinetic drug&#x2010;drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy. CNS Drugs. 2020 Jun;34(6):661&#x2010;672. doi:10.1007/s40263&#x2010;020&#x2010;00726&#x2010;4</Citation></Reference><Reference><Citation>Morrison G, Crockett J, Blakey G, Sommerville K. A phase 1, open&#x2010;label, pharmacokinetic trial to investigate possible drug&#x2010;drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019 Nov;8(8):1009&#x2010;1031. doi:10.1002/cpdd.665</Citation></Reference><Reference><Citation>Gunning B, Mazurkiewicz&#x2010;Be&#x142;dzi&#x144;ska M, Chin RFM, et al. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurol Scand. 2021 Feb;143(2):154&#x2010;163. doi:10.1111/ane.13351</Citation></Reference><Reference><Citation>Ho JJY, Goh C, Leong CSA, Ng KY, Bakhtiar A. Evaluation of potential drug&#x2010;drug interactions with medical cannabis. Clin Transl Sci. 2024;17(5):e13812. doi:10.1111/cts.13812</Citation></Reference><Reference><Citation>European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), European drug report 2024: Cannabis [Webpage], European Monitoring Centre for Drugs and Drug Addiction, 2024. https://www.euda.europa.eu/publications/european-drug-report/2024/cannabis_en</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41628868</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7573</ISSN><JournalIssue CitedMedium="Internet"><Volume>361</Volume><PubDate><Year>2026</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of ethnopharmacology</Title><ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation></Journal><ArticleTitle>Material basis and mechanism of Tangzhiqing in alleviating diabetic atherosclerosis: integrated serum pharmacochemistry, pharmacokinetics, metabolomics, bile acid profiling and 16S rRNA sequencing study.</ArticleTitle><Pagination><StartPage>121290</StartPage><MedlinePgn>121290</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2026.121290</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-8741(26)00141-8</ELocationID><Abstract><AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Diabetic atherosclerosis (DA), characterized by disordered glucose and lipid metabolism, represents a significant metabolic vascular complication. Tangzhiqing (TZQ) has traditionally been used to treat diabetes and its complications. However, its material basis and mechanism for DA remain require further investigation.</AbstractText><AbstractText Label="AIM OF STUDY" NlmCategory="OBJECTIVE">This research aimed to systematically elucidate the pharmacological material basis and underlying mechanism of the traditional Chinese medicine TZQ in diabetic atherosclerosis model mice.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This study established UPLC-MS/MS and UPLC-Q-TOF/MS methods to detect composition and content of TZQ in vivo and in vitro, with pharmacokinetic analysis determining plasma concentration changes of representative components. DA model was induced by western diet and streptozotocin injection in ApoE<sup>-/-</sup> mice. Mice received TZQ (2.5&#xa0;g/kg) for 12 weeks, with metformin as a positive control. Anti-DA effects were evaluated through blood glucose, lipid profiles, and aortic histopathology. Metabolomics and network pharmacology identified key therapeutic pathways. Targeted bile acid metabolomics and 16S rRNA sequencing were employed to assess bile acid profiles in 3 and gut microbiota composition. Subsequent western blot analysis and molecular docking experiments validated the effects of TZQ on key proteins including FXR and CYP7A1.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">118 compounds were identified from TZQ. It contains categories such as organic acids, quinones, flavonoids, alkaloids, and terpenoids. Among them, 39 compounds were absorbed into bloodstream. Pharmacokinetic analysis demonstrated that 18 compounds were effectively absorbed into plasma with appropriate bioavailability. Pharmacodynamic results demonstrated that TZQ significantly alleviated hyperglycemia, hyperlipidemia, and aortic pathology in DA mice. Metabolomics and network pharmacology suggested the anti-DA effects were associated with bile acid metabolism. Targeted analysis confirmed TZQ restored high-fat-diet-induced bile acid metabolic imbalance. 16S rRNA sequencing revealed TZQ modulated gut microbiota dysbiosis, specifically regulating bile acid metabolism-related genera (e.g., Desulfovibrio, Bacteroides, Lactobacillus). The WB results showed that TZQ enhanced the expression of FXR, SHP and CYP7A1 in liver. Molecular docking proved that the bioactive compounds of TZQ exhibits favorable affinity for both FXR and CYP7A1.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study provided a comprehensive detection of in vitro and in vivo constituents and pharmacokinetic profile of TZQ, establishing a foundation for further exploration of its pharmacologically active components. TZQ alleviated DA by regulating the gut microbiota and bile acid metabolism. These results created a new perspective for the management of DA.</AbstractText><CopyrightInformation>Copyright &#xa9; 2026 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xuelian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, No. 69 Zengchan Road, Hebei District, Tianjin, 300250, China; Tianjin University of Traditional Chinese Medicine, No.10 Poyanghu Road, TuanboNew Town, Jinghai District, Tianjin, 301617, China. Electronic address: gxl1053@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fengying</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, No. 69 Zengchan Road, Hebei District, Tianjin, 300250, China; Tianjin University of Traditional Chinese Medicine, No.10 Poyanghu Road, TuanboNew Town, Jinghai District, Tianjin, 301617, China. Electronic address: 17861625832@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Hongli</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, No. 69 Zengchan Road, Hebei District, Tianjin, 300250, China; Tianjin University of Traditional Chinese Medicine, No.10 Poyanghu Road, TuanboNew Town, Jinghai District, Tianjin, 301617, China. Electronic address: 15143108540@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yaxue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, No. 69 Zengchan Road, Hebei District, Tianjin, 300250, China; Tianjin University of Traditional Chinese Medicine, No.10 Poyanghu Road, TuanboNew Town, Jinghai District, Tianjin, 301617, China. Electronic address: syx20200620@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xinran</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, No. 69 Zengchan Road, Hebei District, Tianjin, 300250, China; Tianjin University of Traditional Chinese Medicine, No.10 Poyanghu Road, TuanboNew Town, Jinghai District, Tianjin, 301617, China. Electronic address: 462269846@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, No. 69 Zengchan Road, Hebei District, Tianjin, 300250, China. Electronic address: tianshuang090@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, No. 69 Zengchan Road, Hebei District, Tianjin, 300250, China. Electronic address: hyh101@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ziqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, No. 69 Zengchan Road, Hebei District, Tianjin, 300250, China. Electronic address: lzqpharm@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>J Ethnopharmacol</MedlineTA><NlmUniqueID>7903310</NlmUniqueID><ISSNLinking>0378-8741</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001647">Bile Acids and Salts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012336">RNA, Ribosomal, 16S</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001647" MajorTopicYN="Y">Bile Acids and Salts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="Y">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012336" MajorTopicYN="N">RNA, Ribosomal, 16S</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074085" MajorTopicYN="N">Mice, Knockout, ApoE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091484" MajorTopicYN="N">Network Pharmacology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bile acids</Keyword><Keyword MajorTopicYN="N">Diabetic atherosclerosis</Keyword><Keyword MajorTopicYN="N">FXR</Keyword><Keyword MajorTopicYN="N">Gut microbiota</Keyword><Keyword MajorTopicYN="N">Metabolomics</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">Tangzhiqing</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2026</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>12</Day><Hour>0</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>3</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>2</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41628868</ArticleId><ArticleId IdType="doi">10.1016/j.jep.2026.121290</ArticleId><ArticleId IdType="pii">S0378-8741(26)00141-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41606802</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-7197</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>Metabolic effects of testosterone therapy in transgender and gender diverse individuals with polycystic ovary syndrome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dgag032</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1210/clinem/dgag032</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Polycystic ovary syndrome (PCOS) affects 10 to 13% of individuals assigned female at birth (AFAB), although a greater prevalence is reported in transgender/gender diverse individuals (TGD) (23.8%-38.8%). Testosterone therapy (TT) in TGD individuals is linked to worsening cardiovascular risk factors (CVRF) . Whether TT induces more adverse cardiometabolic changes in TGD with PCOS than TGD without PCOS remains uncertain.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the effects of TT on CVRF in TGD with and without PCOS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively reviewed 373 records to identify 62 TGD with PCOS (withestablished guideline criteria) and 132 age-matched TGD without PCOS. Data included longitudinal anthropometric measurements, hormone and metabolic parameters, and CVRF before and after TT. Group comparison of PCOS vs. without PCOS before and after TT was conducted via independent t-tests, Mann-Whitney-U, and Chi-square.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At baseline, TGD with PCOS had significantly greater body mass index (BMI), obesity prevalence, and, after controlling for BMI, baseline metformin use. There were no significant differences between TGD with and without PCOS when comparing intra-participant changes after TT. Controlling for BMI, TGD with PCOS on TT exhibited significantly greater hyperlipidemia prevalence, alanine transaminase (ALT) levels, and bioavailable testosterone concentrations than TGD without PCOS on TT.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">. Greater baseline cardiometabolic risk was largely BMI-related in TGD with PCOS compared to TGD without PCOS. Only hyperlipidemia and elevated ALT were more prevalent during TT after adjusting for BMI. These findings support cardiometabolic monitoring during TT in all TGD individuals without significant increased risk with PCOS history.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herndon</LastName><ForeName>Justine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5665-0617</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNeil</LastName><ForeName>J Anderson</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winter</LastName><ForeName>Salym</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Alice Y</ForeName><Initials>AY</Initials><Identifier Source="ORCID">0000-0001-7108-0499</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Transmasculine</Keyword><Keyword MajorTopicYN="N">androgen excess</Keyword><Keyword MajorTopicYN="N">cardiovascular risk</Keyword><Keyword MajorTopicYN="N">gender-affirming hormone therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>29</Day><Hour>7</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>29</Day><Hour>7</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>29</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41606802</ArticleId><ArticleId IdType="doi">10.1210/clinem/dgag032</ArticleId><ArticleId IdType="pii">8443989</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>